Decision Diagnostics Corp.

QUARTERLY REPORT FOR OTC PINK

Supplemental Disclosures

Quarterly Report for Year Ended

June 30, 2018

Trading Symbol: **DECN**
CUSIP Number: **243443 108**

Decision Diagnostics Corp.

OTC Pink Basic Disclosure Guidelines

1) Name of the issuer and its predecessors (if any)

In answering this item, please also provide any names used by predecessor entities in the past five years and the dates of the name changes.

DECISION DIAGNOSTICS CORP. (11/25/2011-present)
INSTACARE CORP. (through 11/25/2011)

2) Address of the issuer's principal executive offices

Company Headquarters
Address 1: 2660 TOWNSGATE ROAD
Address 2: SUITE 300
Address 3: WESTLAKE VILLAGE, CA 91361
Phone: 805-446-1973
Email: info@decisiondiagnostics.com
Website(s): www.decisiondiagnostics.com

IR Contact N/A

3) Security Information

Trading Symbol: DECN
Exact title and class of securities outstanding: COMMON
CUSIP: **243443 108**
Par or Stated Value: $0.001
Total shares authorized: 494,995,000 as of: 06/30/2018
Total shares outstanding: **126,643,110** as of: 06/30/2018

Additional class of securities (if necessary):
Trading Symbol: N/A
Exact title and class of securities outstanding: PREFERRED
CUSIP: N/A
Par or Stated Value: $0.001
Total shares authorized: 3,738,500 as of: 06/30/2018
Total shares outstanding: N/A as of: 06/30/2018

Additional class of securities (if necessary):
Trading Symbol: N/A
Exact title and class of securities outstanding: PREFERRED SERIES "B"
CUSIP: N/A
Par or Stated Value: $0.001
Total shares authorized: 2,500 as of: 06/30/2018
Total shares outstanding: 1,000 as of: 06/30/2018*

(*) The company rescinded all outstanding Preferred B shares during 1Q 2018 resulting from criminal issues surrounding the sole Preferred B shareholder. Cancellation of the Preferred B Designations with the State of Nevada Secretary of State will occur in 3Q 2018.

Additional class of securities (if necessary):
Trading Symbol: N/A
Exact title and class of securities outstanding: PREFERRED SERIES "C"
CUSIP: N/A
Par or Stated Value: $0.001
Total shares authorized: 10,000 as of: 06/30/2018
Total shares outstanding: 6,893 as of: 06/30/2018

Additional class of securities (if necessary):
Trading Symbol: N/A
Exact title and class of securities outstanding: PREFERRED SERIES "D"
CUSIP: N/A
Par or Stated Value: $0.001
Total shares authorized: 1,250 as of: 06/30/2018
Total shares outstanding: 40 as of: 06/30/2018

Additional class of securities (if necessary):
Trading Symbol: N/A
Exact title and class of securities outstanding: PREFERRED SERIES "E"
CUSIP: N/A
Par or Stated Value: $0.001
Total shares authorized: 1,250,000 as of: 06/30/2018
Total shares outstanding: 882,540 as of: 06/30/2018*

(*) The company rescinded 271,428 Preferred E shares during 2Q 2018 resulting from criminal issues surrounding a Preferred E shareholder. Additional rescission actions are expected in 3Q 2018 concerning this Preferred E holder.

Transfer Agent
Name: ACTION STOCK TRANSFER CORP.
Address 1: 2469 E. FORT UNION BLVD.
Address 2: SUITE 214
Address 3: SALT LAKE CITY, UT 84121
Phone: 801-274-1088

Is the Transfer Agent registered under the Exchange Act?* Yes: XX No: ☐

*To be included in the OTC Pink Current Information tier, the transfer agent must be registered under the Exchange Act.

In April 2015 the company completed voluntary disclosure, periodic financial, and management's discussion and analysis filings (postings) with OTCMarkets, for the purposes of becoming a current voluntary filer. The company's filings were reviewed and the company was granted current filer status with OTCMarkets on April 21, 2015. The company had to repeat this process in August 2016.

List any restrictions on the transfer of security:

None

Describe any trading suspension orders issued by the SEC in the past 12 months.

None

List any stock split, stock dividend, recapitalization, merger, acquisition, spin-off, or reorganization either currently anticipated or that occurred within the past 12 months:

1:14 reverse stock split of $0.001 par value common stock effective 11/25/2011

4) Issuance History

List below any events, in chronological order, that resulted in changes in total shares outstanding by the issuer in the past two fiscal years and any interim period. The list shall include all offerings of equity securities, including debt convertible into equity securities, whether private or public, and all shares or any other securities or options to acquire such securities issued for services, describing (1) the securities, (2) the persons or entities to whom such securities were issued and (3) the services provided by such persons or entities. The list shall indicate:

COMMON STOCK

Date	Description	Change in Shares	Running Total
12/1/2011	1 for 14 Reverse Split	8,461,032	8,461,032
12/19/2011	New Issuance-Kimberly Binder	75	8,461,107
12/19/2011	New Issuance-Patrick DiParini	200	8,461,307
12/30/2011	10% Stock Dividend	846,669	9,307,976
1/3/2012	DTC Rounding shares	(42)	9,307,934
1/4/2012	New Issuance-Positive Revolution Inc-S-8	100,000	9,407,934
1/11/2012	Converted to Common-Alpha Credit	294,000	9,701,934
1/18/2012	New Issuance-Debt Conv. Andrew Edenbaum	53,354	9,755,288
1/23/2012	DTC Rounding shares	25	9,755,313
3/5/2012	New Issuance-JFS Investments Inc	60,000	9,815,313
3/5/2012	New Issuance-Garden State Securities	60,000	9,875,313
3/5/2012	New Issuance-Excell Advisors	30,000	9,905,313
3/5/2012	Return to Treasury-Positive Revolution	(100,000)	9,805,313
3/5/2012	New Issuance-TPC Holdings Group-ESOP-06	300,000	10,105,313
3/5/2012	New Issuance-Cadence Consulting-ESOP-06	50,000	10,155,313
3/30/2012	New Issuance-Alpha Credit Resources	238	10,155,551
6/27/2012	New Issuance-Rocio C Carazas-ESOP-06	375,000	10,530,551
6/27/2012	New Issuance-Marjolein Imfeld-ESOP-06	375,000	10,905,551
9/26/2012	Converted to Common-Centurion	172,200	11,077,751
10/9/2012	New Issuance-Aubyn Inc-ESOP-06	400,000	11,477,751
11/8/2012	Return to Treasury-Aubyn Inc-ESOP-06	(200,000)	11,277,751
11/8/2012	New Issuance-Mayer & Assoc. Esop-04	650,000	11,927,751
11/8/2012	New Issuance-Mayer & Associates	200,000	12,127,751
11/8/2012	New Issuance-Curing Capital Inc	400,000	12,527,751
11/13/2012	Converted to Common-Centurion	182,000	12,709,751
11/13/2012	New Issuance-Econ Corporate Services	50,000	12,759,751
11/13/2012	New Issuance-Call Van Zant-ESOP-06	100,000	12,859,751
11/13/2012	New Issuance-Darren Bankstead-ESOP-06	50,000	12,909,751
11/13/2012	New Issuance-Axiom Financial Inc	200,000	13,109,751
12/21/2012	Cancellation-Mayer & Associates LLC	(200,000)	12,909,751
12/21/2012	New Issuance-Mayer & Associates LLC	1,000,000	13,909,751
1/7/2013	New Issuance-Mayer & Associates LLC	50,000	13,959,751
1/7/2013	Converted to Common-Apex Clearing	210,000	14,169,751
1/7/2013	Converted to Common-Apex Clearing	236,600	14,406,351
2/15/2013	New Issuance-TPC Holdings Group-ESOP	1,325,000	15,731,351
2/15/2013	New Issuance-Envisionte LLC-ESOP	700,000	16,431,351
2/15/2013	New Issuance-Bridgeview Capital Group ESOP	700,000	17,131,351

2/15/2013	New Issuance-Cadence Holdings LLC ESOP	275,000	17,406,351
2/15/2013	New Issuance-AAC Group LLC ESOP	600,000	18,006,351
2/15/2013	New Issuance-Cadence Holdings LLC ESOP	150,000	18,156,351
2/15/2013	New Issuance-St Andrews Inc	1,000,000	19,156,351
2/15/2013	New Issuance-Alan Binder ESOP	100,000	19,256,351
2/15/2013	New Issuance-Dale Richter ESOP	100,000	19,356,351
2/15/2013	New Issuance-Kimberly Binder ESOP	50,000	19,406,351
2/15/2013	New Issuance-Maria Luz Johnson-ESOP	25,000	19,431,351
2/18/2013	Converted to Common-Apex Clearing	324,800	19,756,151
2/22/2013	New Issuance-Robert Herskowitz ESOP	500,000	20,256,151
2/22/2013	New Issuance-Jeff Whitelaw	125,000	20,381,151
2/22/2013	New Issuance-Brent England	75,000	20,456,151
5/9/2013	Converted to Common-Apex Clearing	868,000	21,324,151
5/10/2013	Cancellation-Robert Herskowitz ESOP	(500,000)	20,824,151
5/10/2013	Cancellation-St. Andrews	(1,000,000)	19,824,151
5/10/2013	New Issuance-Chase Financing Inc ESOP	350,000	20,174,151
5/10/2013	New Issuance-Mayer & Associates LLC ESOP	1,000,000	21,174,151
8/7/2013	New Issuance-St Andrews Inc ESOP	500,000	21,674,151
8/15/2013	New Issuance-Robert Herskowitz ESOP	25,000	21,699,151
8/27/2013	Cancellation-Curring Capital	(200,000)	21,499,151
8/27/2013	Cancellation-ACC Group ESOP	(600,000)	20,899,151
8/27/2013	New Issuance-Benjamin Mayer ESOP	950,000	21,849,151
9/20/2013	New Issuance-SLCC Partners LLC	1,000,000	22,849,151
9/20/2013	New Issuance-Envisionte LLC-ESOP	500,000	23,349,151
9/20/2013	New Issuance-Thomas Hanson-ESOP	250,000	23,599,151
9/20/2013	New Issuance-Envisionte LLC-ESOP	250,000	23,849,151
10/2/2013	New Issuance-Joanne Broeders-ESOP	235,300	24,084,451
10/2/2013	Cancellation-Alan Binder ESOP	(100,000)	23,984,451
10/2/2013	New Issuance-Kimberly Binder	100,000	24,084,451
10/2/2013	Converted to Common-COR Clearing	1,078,000	25,162,451
10/28/2013	Converted to Common-Michael Belcher	350,000	25,512,451
10/28/2013	New Issuance	2,798,728	28,311,179
10/30/2013	New Issuance-Benjamin Mayer ESOP	100,000	28,411,179
10/30/2013	New Issuance-Benjamin Mayer	300,000	28,711,179
10/30/2013	New Issuance	166,365	28,877,544
11/11/2013	Conversion-Centurion Credit	980,000	29,857,544
11/11/2013	New Issuance-Benjamin Mayer ESOP	500,000	30,357,544
11/11/2013	New Issuance	125,000	30,482,544
12/4/2013	Conversion-Centurion Credit	1,220,800	31,703,344
12/23/2013	New Issuance-Mark Herskowitz ESOP	175,000	31,878,344
12/23/2013	New Issuance-Benjamin Mayer ESOP	600,000	32,478,344
12/23/2013	New Issuance	1,200,548	33,678,892
1/2/2014	New Issuance	2,709,678	36,388,570
1/15/2014	New Issuance	748,720	37,137,290
1/15/2014	New Issuance	267,105	37,404,395
2/18/2014	Conversion-Alpha Credit	611,940	38,016,335
2/18/2014	Conversion-Michael Belcher	350,000	38,366,335
2/19/2014	Conversion-Mayer & Associates	798,000	39,164,335
3/28/2014	Conversion-Alpha Credit	523,740	39,688,075
3/28/2014	New Issuance	400,000	40,088,075
6/3/2014	Conversion-Alpha Credit	499,996	40,588,071
6/4/2014	Conversion-Mayer & Associates	1,115,660	41,703,731

8/14/2014	Conversion-Alpha Credit	245,000	41,948,731
8/15/2014	Conversion-Mayer & Associates	550,000	42,498,731
9/9/2014	Conversion-Mayer & Associates	775,000	43,273,731
10/28/2014	Conversion	675,010	43,948,741
1/21/2015	New Issuance	1,875,000	45,823,741
1/28/2015	New Issuance	850,000	46,673,741
2/23/2015	Conversion-Alpha Credit	705,124	47,378,865
5/11/2015	New Issuance-Momona Capital	235,000	47,613,865
5/12/2015	Conversion-Mayer & Associates	950,040	48,563,905
5/12/2015	New Issuance-Robert Herskowiz	950,000	49,513,905
5/21/2015	New Issuance-Momona Capital	235,000	49,748,905
6/1/2015	New Issuance-Chase Financing 401K	533,334	50,282,239
6/8/2015	New Issuance-Momona Capital	437,250	50,719,489
6/8/2015	New Issuance-St Andrews	350,000	51,069,489
6/29/2015	New Issuance-Alpha Capital Anstalt	384,537	51,454,026
7/27/2015	New Issuance-Alpha Capital Anstalt	387,907	51,841,933
8/24/2015	New Issuance-Alpha Capital Anstalt	313,022	52,154,955
9/16/2015	Conversion-Mayer & Associates	1,890,000	54,044,955
9/16/2015	Conversion-Robert Herskowitz	1,400,000	55,444,955
10/27/2015	New Issuance-Alpha Capital Anstalt	479,489	55,924,444
12/2/2015	New Issuance-Alpha Capital Anstalt	950,545	56,874,989
12/15/2015	New Issuance-Alpha Capital Anstalt	950,545	57,825,534
12/21/2015	New Issuance-Alpha Capital Anstalt	956,950	58,782,484
2/2/2016	New Issuance-Alpha Capital Anstalt	970,980	59,753,464
2/17/2016	New Issuance-Alpha Capital Anstalt	1,614,248	61,367,712
2/25/2016	New Issuance-Robert Herskowiz	750,000	62,117,712
3/21/2016	New Issuance-Paradigm Capital Holdings	1,400,000	63,517,712
3/21/2016	New Issuance-Robert Herskowitz	200,000	63,717,712
3/29/2016	New Issuance-Alpha Capital Anstalt	404,630	64,122,342
3/29/2016	New Issuance-James J Loures	500,000	64,622,342
4/13/2016	New Issuance-Robert Herskowitz	280,000	64,902,342
4/13/2016	New Issuance-Robert Herskowitz	280,000	65,182,342
4/13/2016	New Issuance-Robert Herskowitz 2011 Irv TR	140,000	65,322,342
4/13/2016	New Issuance-Chase Financial	148,160	65,470,502
4/13/2016	New Issuance-Mark Herskowittz	185,195	65,655,697
4/13/2016	New Issuance-Andrew Schoenzeit	37,040	65,692,737
4/13/2016	New Issuance-Robert Herskowitz 2011 Irv TR	431,376	66,124,113
4/26/2016	New Issuance-LICGO Partners	1,837,500	67,961,613
4/26/2016	Conversion-Mayer & Associates	200,200	68,161,813
5/2/2016	New Issuance-Robert Herskowitz	472,106	68,633,919
5/5/2016	New Issuance-Alpha Capital Anstalt	998,099	69,632,018
5/17/2016	New Issuance-Alpha Capital Anstalt	422,669	70,054,687
5/17/2016	New Issuance-Navesink	625,000	70,679,687
5/18/2016	New Issuance-LICGO Partners	525,000	71,204,687
5/18/2016	Conversion-Mayer & Associates	220,000	71,424,687
6/1/2016	New Issuance-Alpha Capital Anstalt	814,314	72,239,001
6/6/2016	New Issuance-Mark Herskowitz	1,000,000	73,239,001
6/6/2016	New Issuance-Chase Financing Inc Profit Sh.	1,050,000	74,289,001
6/6/2016	New Issuance-Robert Herskowitz	280,000	74,569,001
6/6/2016	New Issuance-Robert Herskowitz 2011 Irv TR	70,000	74,639,001
6/8/2016	New Issuance-Alpha Capital Anstalt	484,148	75,123,149
6/27/2016	New Issuance-Navesink	625,000	75,748,149

7/18/2016	New Issuance-Cadence Holdings LLC	100,000	75,848,149
7/18/2016	New Issuance-TPC Holdings Group	150,000	75,998,149
7/21/2016	New Issuance-Robert Herskowitz	700,000	76,698,149
7/21/2016	New Issuance-Robert Herskowitz 2011 Irv TR	70,000	76,768,149
7/21/2016	New Issuance-Chase Financial	945,000	77,713,149
8/2/2016	New Issuance-Navesink	625,000	78,338,149
8/29/2016	New Issuance-Alpha Capital Anstalt	954,925	79,293,074
9/7/2016	New Issuance-Chase Financial	945,000	80,238,074
9/19/2016	New Issuance-Alpha Capital Anstalt	521,784	80,759,858
9/19/2016	New Issuance-Mark Herskowitz	805,147	81,565,005
9/19/2016	New Issuance-Marc Berger	400,000	81,965,005
11/21/2016	New Issuance-Alpha Capital Anstalt	957,485	82,922,490
12/6/2016	New Issuance-Alpha Capital Anstalt	962,118	83,884,608
12/12/2016	New Issuance-LICGO Partners	755,300	84,639,908
1/9/2017	New Issuance-Alpha Capital Anstalt	971,074	85,610,982
1/9/2017	New Issuance-Mark Herskowitz	400,000	86,010,982
3/1/2017	New Issuance-Alpha Capital Anstalt	989,425	87,000,407
3/3/2017	New Issuance-Chase Financial	1,400,000	88,400,407
3/3/2017	New Issuance-Robert Herskowitz	560,000	88,960,407
3/3/2017	New Issuance-R Herskowitz 2011 Irrv. TR	140,000	89,100,407
3/10/2017	Issuance-Mark Herskowitz	400,000	89,500,407
3/21/2017	New Issuance-Alpha Capital Anstalt	355,803	89,856,210
4/19/2017	New Issuance-Paradigm Capital Holdings	400,000	90,256,210
5/10/2017	New Issuance-Navesink	625,000	90,881,210
5/17/2017	New Issuance-OmniVance Advisors LLC	100,000	90,981,210
6/19/2017	New Issuance-Alpha Capital Anstalt	1,096,312	92,077,522
7/11/2017	New Issuance-Robert Herskowitz	1,400,000	93,477,522
7/11/2017	New Issuance-Chase Financial	1,400,000	94,877,522
7/24/2017	New Issuance-Navesink	625,000	95,502,522
7/24/2017	New Issuance-Paradigm Capital Holdings	1,475,000	96,977,522
8/1/2017	New Issuance-Mark Herskowitz	350,000	97,327,522
8/7/2017	New Issuance-Alpha Capital Anstalt	981,067	98,308,589
8/21/2017	New Issuance-Alpha Capital Anstalt	971,043	99,279,632
8/24/2017	New Issuance-R Herskowitz 2011 Irrv. TR	700,000	99,979,632
9/5/2017	New Issuance-Mark Herskowitz	350,000	100,329,632
9/20/2017	New Issuance-Alpha Capital Anstalt	952,043	101,281,675
10/3/2017	New Issuance-Alpha Capital Anstalt	987,640	102,269,315
10/23/2017	New Issuance-Alpha Capital Anstalt	991,943	103,261,258
11/6/2017	New Issuance-Mark Herskowitz	500,000	103,761,258
11/6/2017	New Issuance-Alpha Capital Anstalt	2,878,058	106,639,316
12/4/2017	New Issuance-Alpha Capital Anstalt	1,502,294	108,141,610
12/6/2017	New Issuance-Chase Financing Inc	700,000	108,841,610
12/12/2017	New Issuance-Scott J Weiner	1,000,000	109,841,610
12/19/2017	New Issuance-Robert Herskowitz	1,400,000	111,241,610
12/31/2017	Cancellation-Scott J Weiner	(1,000,000)	110,241,610
1/8/2018	New Issuance-Alpha Capital Anstalt	1,504,281	111,745,891
2/9/2018	New Issuance-Alpha Capital Anstalt	1,496,661	113,242,552
2/23/2018	New Issuance-Robert Herskowitz	1,400,000	114,642,552
2/23/2018	New Issuance-Chase Financing Inc Profit Sh.	980,000	115,622,552
3/5/2018	New Issuance-Alpha Capital Anstalt	1,510,797	117,133,349
4/2/2018	New Issuance-Alpha Capital Anstalt	1,521,904	118,655,253
4/3/2018	New Issuance-Mark Herskowitz	849,123	119,504,376

4/16/2018	New Issuance-Alpha Capital Anstalt	1,513,789	121,018,165
4/23/2018	New Issuance-Alpha Capital Anstalt	1,039,571	122,057,736
5/29/2018	New Issuance-Alpha Capital Anstalt	1,985,374	124,043,110
5/29/2018	New Issuance-Robert Herskowitz	1,550,000	125,593,110
6/11/2018	New Issuance-Chase Financing Inc Profit Sh.	1,050,000	126,643,110

PREFERRED B STOCK

Date	Description	Change in Shares	Running Total
3/23/2011*	New Issuance-Centurion Credit Resources	1,000	1,000

PREFERRED C STOCK

Date	Description	Change in Shares	Running Total
1/4/2012	New Issuance-Michael Belcher	1,250	1,250
8/27/2013	New Issuance-Lathrop Gage LLC	1,500	2,750
10/28/2013	Conversion-Michael Belcher	(70)	2,680
2/18/2014	Conversion-Michael Belcher	(70)	2,610
12/30/2015	New Issuance-Navesink Device Initiatives	1,475	4,085
3/21/2016	New Issuance-Paradigm Capital	800	4,885
4/26/2016	New Issuance-LICGO Partners	1,050	5,935
4/26/2016	New Issuance-Paradigm Capital	325	6,260
5/17/2016	Conversion-Navesink Device	(125)	6,135
5/18/2016	New Issuance-LICGO Partners	300	6,435
5/18/2016	New Issuance-Paradigm Capital	50	6,485
6/27/2016	Conversion-Navesink Device	(125)	6,360
8/2/2016	Conversion-Navesink Device	(125)	6,235
4/19/2017	Conversion-Paradigm Capital	(80)	6,155
4/19/2017	New Issuance-LICGO Partners	157	6,312
5/10/2017	Conversion-Navesink Device	(125)	6,187
7/24/2017	Conversion-Navesink Device	(125)	6,062
7/24/2017	Conversion-Paradigm Capital	(295)	5,767
7/25/2017	New Issuance-LICGO Partners	196	5,963
9/28/2017	New Issuance-Gerald Hickson	300	6,263
10/23/2017	New Issuance-LICGO Partners	210	6,473
1/18/2018	New Issuance-LICGO Partners	210	6,683

PREFERRED D STOCK

Date	Description	Change in Shares	Running Total
12/31/2017	New Issuance-Sovereign Partners	40	40

PREFERRED E STOCK

Date	Description	Change in Shares	Running Total
8/1/2008	New Issuance-Centurion Credit	14,900	14,900
11/5/2008	New Issuance-Centurion Credit	21,225	36,125
12/16/2008	New Issuance-Centurion Credit	30,785	66,910
1/15/2009	New Issuance-Centurion Credit	40,000	106,910
3/31/2009	New Issuance-Centurion Credit	23,000	129,910
3/31/2009	New Issuance-Centurion Credit	19,000	148,910
4/1/2009	Converted to Common	(14,900)	134,010
5/13/2009	New Issuance-Centurion Credit	17,800	151,810
6/2/2009	New Issuance-Centurion Credit	25,000	176,810

7/8/2009	New Issuance-Centurion Credit	25,000	201,810
8/13/2009	New Issuance-Centurion Credit	13,000	214,810
9/11/2009	New Issuance-Centurion Credit	12,600	227,410
10/7/2009	New Issuance-Centurion Credit	20,000	247,410
11/4/2009	New Issuance-Centurion Credit	16,700	264,110
11/18/2009	New Issuance-Centurion Credit	60,000	324,110
11/20/2009	Converted to Common	(92,010)	232,100
11/23/2009	Converted to Common	(59,800)	172,300
12/7/2009	Converted to Common	(25,000)	147,300
12/8/2009	New Issuance-Centurion Credit	720,000	867,300
1/20/2010	Converted to Common	(25,000)	842,300
2/16/2010	Converted to Common	(13,000)	829,300
3/17/2010	Converted to Common	(12,600)	816,700
4/16/2010	Converted to Common	(20,000)	796,700
5/25/2010	Converted to Common	(16,700)	780,000
6/4/2010	Converted to Common	(60,000)	720,000
7/19/2010	Converted to Common	(10,000)	710,000
8/4/2010	New Issuance-Centurion Credit	200,000	910,000
1/26/2011	Converted to Common	(54,500)	855,500
3/8/2011	New Issuance-Centurion Credit	240,000	1,095,500
5/17/2011	Converted to Common	(135,200)	960,300
5/17/2011	New Issuance-Centurion Credit	135,000	1,095,300
1/11/2012	Converted to Common	(21,000)	1,074,300
3/30/2012	New Issuance-Alpha Credit Resources	124,700	1,199,000
9/26/2012	Converted to Common	(12,300)	1,186,700
11/13/2012	Converted to Common	(13,000)	1,173,700
1/7/2013	Converted to Common	(15,000)	1,158,700
1/7/2013	Converted to Common	(16,900)	1,141,800
2/18/2013	Converted to Common	(23,200)	1,118,600
5/9/2013	Converted to Common	(62,000)	1,056,600
10/2/2013	Converted to Common	(77,000)	979,600
11/11/2013	Conversion-Centurion Credit	(70,000)	909,600
12/4/2013	Conversion-Centurion Credit	(87,200)	822,400
1/15/2014	Conversion-Alpha Credit	(53,480)	768,920
2/18/2014	New Issuance-Mayer & Associates	125,000	893,920
2/18/2014	Conversion-Alpha Credit	(43,710)	850,210
2/19/2014	Conversion-Mayer & Associates	(57,000)	793,210
3/28/2014	Conversion-Alpha Credit	(37,400)	755,810
6/3/2014	Conversion-Alpha Credit	(35,714)	720,096
6/4/2014	Conversion-Mayer & Associates	(79,690)	640,406
8/14/2014	Conversion-Alpha Credit	(17,500)	622,906
8/15/2014	Conversion-Mayer & Associates	(39,285)	583,621
9/9/2014	Conversion-Mayer & Associates	(55,357)	528,264
10/28/2014	Conversion-Mayer & Associates	(30,358)	497,906
1/21/2015	New Issuance-Robert Herskowitz	100,000	597,906
1/21/2015	New Issuance-Mayer & Associates	135,000	732,906
1/21/2015	New Issuance-Alpha Credit Resources	67,860	800,766
2/23/2015	New Issuance-Alpha Credit Resources	(50,366)	750,400
5/12/2015	Conversion-Mayer & Associates	(67,860)	682,540
5/12/2015	New Issuance-Robert Herskowitz	30,000	712,540
7/27/2015	New Issuance-Chase Financing	75,000	787,540
9/16/2015	Conversion-Mayer & Associates	(135,000)	652,540

9/16/2015	Conversion-Robert Herskowitz	(100,000)	552,540
9/16/2015	New Issuance-Chase Financing	135,000	687,540
2/25/2016	New Issuance-Robert Herskowitz	100,000	787,540
3/21/2016	New Issuance-Mayer & Associates	14,300	801,840
4/26/2016	Conversion-Mayer & Associates	(14,300)	787,540
6/6/2016	New Issuance-Mark Herskowitz 401K Trust	100,000	873,240
6/6/2016	New Issuance-Chase Financing Inc Profit Sh.	35,000	908,240
6/6/2016	New Issuance-Chase Financing	100,000	1,008,240
6/6/2016	Conversion-Chase Financing Inc Profit Sh.	(75,000)	933,240
7/21/2016	Conversion-Chase Financing Inc	(67,500)	865,740
7/21/2016	Conversion-Robert Herskowitz	(30,000)	835,740
9/7/2016	Conversion-Chase Financing Inc	(67,500)	768,240
9/19/2016	New Issuance-Chase Financing Inc Profit Sh.	75,000	843,240
1/9/2017	New Issuance-Chase Financing Inc Profit Sh.	105,000	948,240
3/3/2017	Cancellation	(105,000)	843,240
3/3/2017	New Issuance-Chase Financing	50,000	893,240
3/3/2017	New Issuance-Chase Financing Inc Profit Sh.	70,000	963,240
3/3/2017	Conversion-Chase Financing	(100,000)	863,240
5/17/2017	New Issuance-Chase Financing	100,000	963,240
7/11/2017	Conversion-Robert Herskowitz	(100,000)	863,240
7/11/2017	Conversion-Chase Financing	(100,000)	763,240
8/24/2017	New Issuance-Chase Financing	50,000	813,240
8/24/2017	New Issuance-Chase Financing Inc Profit Sh.	50,000	863,240
8/24/2017	New Issuance-Chase Financing	50,000	827,540
8/24/2017	New Issuance-Chase Financing Inc Profit Sh.	50,000	877,540
12/6/2017	New Issuance-Chase Financing	(50,000)	827,540
12/12/2017	New Issuance-Robert Herskowitz	100,000	927,540
12/19/2017	Conversion-Robert Herskowitz	(100,000)	827,540
12/31/2017	Cancellation-Benjamin Mayer (2016 Issuance)	(14,300)	813,240
01/18/2018	New Issuance-Robert Herskowitz	100,000	913,240
02/23/2018	Conversion-Robert Herskowitz	(100,000)	813,240
02/23/2018	Conversion-Chase Financing Inc Profit Sh.	(70,000)	743,240
04/16/2018	New Issuance-Chase Financing Inc Profit Sh.	100,000	857,540
05/11/2018	New Issuance-Chase Financing Inc Profit Sh.	100,000	957,540
06/11/2018	Conversion-Chase Financing Inc Profit Sh.	(75,000)	882,540

A. Whether the certificates or other documents that evidence the shares contain a legend (1) stating that the shares have not been registered under the Securities Act and (2) setting forth or referring to the restrictions on transferability and sale of the shares under the Securities Act.

See above

5) Financial Statements

SEE FINANCIAL STATEMENTS ATTACHED TO THIS DISCLOSURE STATEMENT

6) Describe the Issuer's Business, Products and Services

Disclosure

Business Overview

Decision Diagnostics Corp. is a worldwide prescription and non-prescription diagnostics and home testing products distributor and the manufacturer of the and GenUltimate! glucose test strip and the Genstrip 50 (discontinued in November 2016), both Class II medical devices for at-home use for the measurement of glucose. The company also has its GenSure! glucose test strip, the second of its six products, designed for off-shore sales. GenSure! is complete and thoroughly tested, and available for sale, but will primarily be sold as an International private label market entry in the coming months. While the GenUltimate! test strip enjoys wide distribution primarily domestically, the GenSure! test strip will initially be sold by an exclusive distributor in Mexico to a "big box" client who owns or controls a large percentage of Mexican pharmacies and convenience stores. This "big box" also has stores in several South American countries. GenSure! requires a Mexican government registration process which was undertaken by the company's distributor beginning in July 2018. Mexico and India provide the best outlets for the sale on GenSure! test strips and to a lesser extent, GenSure! meters.

The company's GenChoice! glucose test strip is in patient clinical trials in Korea. The trials are going very well and would have been completed by the end of July 2018 had the religious hospital, the host of the trials, not become the subject of a July 2018 medical workers strike. Clinical trials are managed by credentialed third party researchers (the IRB). In this case the IRB was willing to complete the clinicals, but the sponsoring church is recognizing the worker's strike. The company's GenPrecis! test strip and Precise meter, the next of the company's products to undergo clinical trials testing, has passed through its advanced development, is concept proven, and will enter independent third party testing and live patient testing (clinical trials) in 3Q 2018. There will be additional discussions of the GenSure! and GenPrecis! products later in this document.

As an off-shore product, GenSure! is currently undergoing the medical device registration process in Mexico. The GenSure! clinical trials were completed in 4Q 2017 and the product was launched in 4Q 2017. We have engaged an exclusive distributor for GenSure! for the Mexican market, a market that should go "hand in glove" for GenSure! since there are several hundred thousand Mexicans using the legacy meter that GenSure! operates with. GenSure! employs a value proposition based on its less expensive price vs. the legacy products. We have also identified International distributors for GenSure!, most recently in India.

At the conclusion of the respective clinical trials, the GenChoice! and GenPrecis! products will be registered in the EU (both meet the enhanced ISO 2015 standards) and applications for 510K pre-market will be filed with the FDA. The company has contracted with the expert organization that will write the 510K documents and prosecute these documents with FDA staff, along with the company. The draft of the 510K for the GenChoice product has already begun.

The cost of the development, advanced development, independent third party testing, patient testing (clinicals) and the pre-market 510K registration process is approximately $1,250,000 per product. New products development is an extensive and expensive undertaking and requires exquisite planning and implementation, made more complex by the distances involved. The company employs its own U.S. based experts who approve, along with the company, the product development plans and then oversee the implementation of these plans. The company will have five of these product development expenditures in 2018 and 2019. Where possible, the company arranges fixed bids for contract services. These test strip products are not "just paper" as more than a handful of company shareholders and former shareholders have argued.

In the late 2Q 2018 the company moved into the growing pet (dog and cat) testing markets. The company made several changes to its GenChoice! product to address the pet testing market. The new pet testing product is called PetSure! PetSure!, was developed, tested and brought to market in less than 90 days. PetSure! operates on the pet testing industry's legacy meter and has been on sale since July 31, 2018. Initial sales have been very encouraging. Media advertising for the PetSure! product will begin on August 15, 2018. The second product the company is bringing to the market in 4Q 2018 is its PetUltimate! test strip and meter. PetUltimate! will also be based on an existing company technology. The company's plan for the pet testing market is to offer a test strip solution for the leading meter in use, and also to offer a proprietary system (meter and strip) for the retail markets.

The U.S. FDA, in a manner similar to prescription drugs, regulates diagnostic test kits and at-home patient testing products like the company's test strip and meters in a similar but somewhat streamlined process, to the regulation of prescription medicine. The regulatory standard used for the Genstrip 50 was the 510k pre-market and post-market processes. The same process will be used for the GenChoice! and GenPrecis! products beginning with the 510k approval with the FDA during the latter part of 2018. Both the GenChoice! and GenPrecis! products will be sold internationally while the U.S. FDA 510k applications are pending. That is a recent trend for newer glucose testing products and devices.

Previous to this change in business model, from 2005 and until 2013, the company contracted with independent pharmacies for use of their prescription drug distribution licenses. At that time the company made market and sold brand name over the counter pharmaceutical items with a concentration in legacy diabetic test strips. The brand name products we distributed, for the most part, did

not require a doctor's prescription for anything other than insurance benefit compliance. Our previous business model worked well in the previous regulated environment, although the financial benefits were stressed by major changes made to the Federal Medicare plan that have led to substantially lower rates of reimbursement and ultimately an unprofitable business model.

Our Current Business Foundation

Our subsidiaries, Pharma Tech Solutions, Inc., PDA Services, Inc. and PharmaTech Sensor Development Corp. operate in several healthcare products channels. In addition our subsidiary Decision IT Corp. engages in the acquisition and holding of Intellectual Property including Patents and Trademarks and specialty manufacturing equipment acquired for our Korean contract manufacturer of our GenUltimate! and our in development GenSure! GenPrecis! and GenChoice! products. Our newest subsidiary Pharmatech Sensor Development Corp. manages our investment in specialty manufacturing machinery and testing laboratories, as well as an inventory credit line to finance inventory purchases of our test strip and meter products. This credit line will be expanded for the management of our GenChoice! and GenPrecis! products in 2018. The company has discontinued its GenStrip 50 product and ended the selling of the last of the inventory in November 2016.

In March 2017 the company was approached by its Korean partner, The Bio Co., Ltd to design and fund a new product which the company calls GenPrecis!. This product represents a major improvement in diabetic glucose monitoring. The GenPrecis! system will be the first of its kind +/- 9% system. Current ISO (2015) and FDA (2014) guidelines call for glucose monitoring systems to meet a +/- 15% standard, whereby the meter and strip must be within +/- 15% of a reference method in repeated samplings 95% of the time. GenUltimate! and GenChoice! are +/- 15% test strips, but in each case 97+% of the time in repeated samplings. GenPrecis! is designed to meet the written standards of the ISO and FDA at +/- 9%, 97% of the time – effectively setting a new standard. The company has been funding the development of this system product since 2017, as well as a test strip only derivative version for use with two legacy meters sold only overseas. The GenPrecis! system product is ready for testing and will begin tests as soon as the final independent testing on the GenChoice! product is complete later in August 2018. The natural market for this product will be the U.S, and Canada where precision standards are higher for new products. The company plans two types of meter for the GenPrecis! product, a meter for middle-school and high school aged children (Type I diabetics) and a legacy commercial meter.

As of this writing, neither GenSure! nor GenPrecis! is available for sale or distribution in the U.S. or Puerto Rico.

From time to time, when economic conditions warrant and given market conditions, we distribute other brand name prescription and non-prescription diagnostics products, as well as several lines of ostomy, wound care and post-surgery medical products, although these healthcare channels have also undergone two major market changes and disruptions since July 2013 and we have determined that we will maintain our contacts but in 2017 we refrained from competing. Our main product was the Genstrip 50 and its successor brand the GenUltimate!, both of improved performance and component design improvements and a rebranding and development (from scratch) of the original Shasta Technologies Genstrip. In the case of all of the company's products the company owns and manages the product design specifications, the product historical design file and the PDR. The company's current plans include only the design and manufacture of its own products. In the future we may also import finished products from overseas companies in need of a U.S. marketing presence. We maintain an FDA registered contract manufacturer in South Korea. We ended our association with the contract manufacturer in Pennsylvania in 2017.

The original GenStrip, our first product, was cleared for market by the FDA on November 30, 2012. By virtue of our written agreements with Shasta Technologies in 2011, we were granted an irrevocable license to prosecute their 510k application with the U.S. FDA, and we succeeded. This was no small feat. We introduced the original Genstrip in March 2013. We then acquired Genstrip from Shasta Technologies LLC on March 20, 2014 and in late June 2014 we made the first branding changes. We began work on the GenUltimate! product in July 2015 and introduced this improved test strip (vs. our GenStrip) in April 2016. The original Shasta Genstrip and our Genstrip 50 have been discontinued.

Historical Construct

Shasta Technologies LLC, the original specifications provider of GenStrip, had an extremely difficult relationship with the US FDA and was the subject of a detailed and damning FDA (Enforcement) Warning Letter on April 8, 2014, and when they refused to respond to this Warning Letter, the FDA then broadcast a worldwide Safety Notice on April 29, 2014, the FDA version of the Death Penalty. This second letter effectively ended Shasta's ability to be a product design specifier and manufacturer, due to a total lack of regulatory adherence in the highly regulated medical device industry. It is confusing to consider what Shasta could have possibly been thinking. The company's acquisition of Genstrip (now GenUltimate!) was fortuitous in its timing given the finality and outcome of Shasta Technologies' fatal troubles with the FDA.

The worldwide market for at-home blood glucose testing is an estimated $17.2 billion, inclusive of the 2013 and 2016 changes to the Federal Medicare programs which gutted almost one-third of the U.S. market. The current GenUltimate! competes directly with one of the largest worldwide platform manufacturers the venerable Johnson & Johnson (Lifescan Inc.). GenUltimate! (and the earlier GenStrip 50) were developed for use with the OneTouch Ultra legacy system for at-home blood glucose testing, a system currently used daily by over 3 million diabetes afflicted Americans and 5.8 million diabetics world-wide. GenUltimate! competes in the overall at-home testing market by offering an economical solution to former users of the legacy platform provider's product. The company's GenUltimate! product, designed to meet new European Union standards is a much improved version. That being said, the legacy product that GenUtimate! competes with is in decline. Our business model is unique to this market channel as our major business focus is directed toward diabetics who have attempted a change of their glucose monitoring platforms (systems) or those currently using the J&J legacy products but are dealing with escalating prices and lower insurance reimbursements, and frankly better competitive meters. At the time of the introduction of GenStrip in March 2013, J&J controlled just under 30% of this market and 100% of its own Lifescan, Inc. OneTouch Ultra market.

Throughout 2012 in anticipation of the introduction of Genstrip, we evaluated our brand-name distribution model, a model that provided streams of revenue but extremely low profit margins, and over the course of the last 30 months we phased out sales of those brand name products that had been a backbone of our distribution business. In addition the brand name products distribution business created a situation where we had been distributing legacy products that competed directly with our GenUltimate! Phasing out these brand name products lowered our order (revenues) intake but allowed us to become a manufacturer, at a higher level in the greater market channel.

The company will continue to direct its marketing efforts to ambulatory and semi-ambulatory older Americans afflicted with diabetes and complications caused by diabetes and old age.

We began our transition into these medical products channels on November 1, 2011 when we completed the acquisition of Diagnostic Newco LLC from its owner Kimberly Binder. Diagnostic Newco LLC was a design company that specialized in product packaging design, medical products advertising design and graphic art. Ms. Binder joined the staff of the company's Pharma Tech Solutions, Inc. subsidiary specifically for these purposes, and has worked closely with our contract manufacturers for GenUltimate!, making subtle changes to packaging design and more recently integrating new package design with the new FDA UDI product identification data system, among other responsibilities. Ms. Binder is also responsible for the package design for new diagnostic products the company is currently working on, including the GenSure! and the upcoming GenChoice! and GenPrecis! products. All of the company's products will require packaging for domestic sales, International sales, and hybrid private label sales to the "big box." Ms. Binder is also owner of Genstrip Direct LLC and Full Circle Diabetes LLC, her own distribution companies, which she operates independently from her (Decision Diagnostics Corp. and Pharma Tech Solutions, Inc.) company related responsibilities.

We also intend to acquire additional private companies, or partner with small engineering companies that have developed technology requiring either regulatory approval, distribution expertise or both. We are moving quickly to achieve our goal of becoming a vertically integrated, full service value added provider of products and services to an ever-growing market. The at-home diabetes testing market continues to grow as diabetics continue to be diagnosed and treated. The market for diabetes testing products is already in the tens of billions of dollars continues to grow rapidly. We also intend to make additional capital investment later in 2018-2019 in our Korean contract manufacturer and advanced development partner for the manufacture of GenPrecis! and two new products GenAccord! and GenCambre!, both products that will compete with existing legacy products not previously mentioned.

The company's current proprietary product offering, cleared by the FDA for commercial distribution on November 30, 2012, and now in its later branded version, the GenUltimate! blood glucose diagnostic test strip for at-home testing. Genstrip, the original product, is a product originally conceived by Shasta Technologies LLC, who proved incapable of attaining the necessary regulatory approvals after two attempts, 2009 and 2010/2011. In addition the original Shasta concept could not clear the FDA 510K process on the basis of performance when tested on human subjects, and had to undergo major design changes and a new 510K application that was eventually sponsored by us. The original Shasta product was acquired by our Pharma Tech subsidiary on March 20, 2014, and fits

into a diagnostic product niche, fitting nicely into the world-wide self-test (home test) market that has been growing at a 15% annual rate. Since GenUltimate! is a rather unique product offering, employing a brand name razor blade only model (diagnostic test strip) into a razor (diagnostic meter) -- razor blade (diagnostic test strip) market, the Genstrip 510(k) application made for unusual challenges for the FDA and an educational challenge and opportunity for the company. In fact, the company only recently (March 15, 2016) concluded its dealings with the FDA pre and post market review staff, an on-going process that was begun on a sour note by Shasta in October 2009. The company believes that upcoming product offerings such as the GenChoice! and GenPrecis! products, will also be regulated by the FDA but will go through a much smoother review and comment process, particularly since receipt of a directed landmark ruling by the U.S. FDA, covering our third party developed diagnostics (developed, in development and to be developed). Since the company plans additional similar products in the future designed to work on other diagnostic platforms, in fact a product announced still in the current reporting year, the Genstrip/GenUltimate! experience, however slow and unresponsive it was, has provided lessons and experience which is already being put to use.

Until our receipt of the landmark March 2016 ruling from the FDA, two years (and growing) was a standard development to market timeline for in-vitro diagnostic products similar to Genstrip / GenUltimate! In fact the long review periods and stifling performance standards established have contributed to a large decline in new products offerings across the entire industry since 2014. Nonetheless, we are confident that our new products will enjoy a much speedier FDA review process. As a result of previous delays and failures by Shasta Technologies in completing its own FDA 510k approval application, and then problems Shasta encountered in prosecuting its two original applications with FDA staff, the company changed its contractual responsibilities and obligations with Shasta. Further (eventually fatal) on-going problems encountered by Shasta, which on their face proved irresolvable, presented the company with an opportunity that we seized. On March 20, 2014 our Pharma Tech Solutions, Inc. subsidiary acquired the intellectual property, the marks, and the GenStrip cleared 510(k). Subsequently we accomplished a rebranding of the original Genstrip product (as GenUltimate!), built manufacturing protocols, implemented a robust Quality System throughout 2014 and 2015, and then developed the improved GenUltimate! product. GenUltimate! has become the only version of the original Genstrip line that will be packaged to conform with the FDA UDI standards, and was released as UDI compliant as of September 24, 2016. Manufacturing of Genstrip 50 ended and on-going sales continued under the GenUltimate! brand, and includes the FDA UDI packaging.

In June 2010 the company was approached by the largest retailer in the world for the distribution and sale of the Genstrip product, then about to enter the 510k regulatory review process, at over 5,000 retail stores worldwide. A contract with this retailer was negotiated in September 2010 and subsequently renegotiated and renewed in April 2011, and as soon as the retail contract was agreed to and as a means to conduct market research, the company began seeking pre-conditioned letters of intent (pre-orders) for Genstrip, while continuing the prosecution of the 510(k) application on behalf of Shasta Technologies before the FDA. Discussions with this retailer and other similarly situated retailers were placed in a litigation induced hiatus since our litigation with Lifescan, Inc. took a nasty turn. Lifescan Inc., the diabetes testing division of Johnson & Johnson sued the company in three separate suits, all in Federal court, beginning in September 2011. These suits proved costly in that their intended purpose was to keep the Genstrip product off of retail market shelves. Until these suits were settled in May 2016, the company's marketing abilities were severely limited. The company believes there will be additional limitations as long as Johnson & Johnson spends large sums to discredit the company and its products. However, it should be noted that Johnson & Johnson announced in January 2018 that their entire diabetic business (three divisions, multiple products) had been put up for sale, and offers for some or all of their businesses had been received. An offer was accepted by J&J in June 2018 and the sale of the Lifescan, Inc. division is proceeding to a Definitive Agreement. The sale of their Lifescan business, when it occurs, should change the diabetic testing field to a great degree, and in our opinion should bring more positive views of our company in an industry that we have been competing in for six years.

The settlements we did achieve with J&J provided a hard-fought victory for the company, particularly since in 2015 our erstwhile former partner Shasta Technologies had admitted to patent infringements of all three J&J diabetic medical device patents that were being adjudicated. Shasta's admissions were shockers. We settled these lawsuits in a novel manner, where Johnson & Johnson paid the company a settlement amount, for lawsuits where the company was a defendant, a rarity in matters where the payor had initiated the strike suit in the first place. J&J, as a part of the settlement, also granted the company licenses to three J&J patents (including one patent that J&J subsequently lost through final action by the US Supreme Court), the larger value gained from this 5-year legal battle. In March 2016, prior to its settlement, the company's Pharma Tech Solutions, Inc. and Decision IT Corp. subsidiaries brought suit against Lifescan, Inc. in Nevada Federal court for patent infringement, the company alleging that Lifescan, Inc.'s OneTouch Ultra product was and had been infringing both of the company's patents. In March 2017, after a protracted battle with J&J where they tried to invalidate the company's lawsuit, the court in a major ruling agreed that the company will be allowed to move forward (a major victory so early in the suit) and will also be allowed to allege the Doctrine of Equivalents, a legal doctrine that would preclude J&J from twisting words through its pleadings and expert reports to escape justice. In April 2017 the company amended its original suit to include allegations under the Doctrine of Equivalents. That suit is still subject to legal wrangling with a milestone ruling from the trial judge still due. In August 2018 the company filed a letter with the court and specifically the trial judge requesting an immediate ruling.

"The doctrine of equivalents is a legal rule in many (but not all) of the world's patent systems that allows a court to hold a party liable for patent infringement even though the infringing device or process does not fall within the literal scope of a patent claim, but nevertheless is equivalent to the claimed invention(s)."

Further, in January 2016 the US Supreme Court ruled that the Doctrine of Laches, a defense used by many Defendants in patent infringement suits could no longer be used. This ruling further deprived J&J of one of its most important defenses against the company's current patent infringement claims. The company remains optimistic that we will prevail in this lawsuit seeking compensation from J&J for patent related damages or in its stead, a fair settlement.

The Current Business

Currently the diabetes testing market is dominated by four large pharmaceutical manufacturers who provide very similar and equally focused products, selling at essentially equal prices. Genstrip's original introduction, even with the fits and starts, employed a business model different than those models employed by the major market players. Recent successes in the on-line marketplace has allowed the company to alter the market dynamics, lowering average price (which has occurred) or allowing for increased testing by diabetics for a lesser price, thereby affecting all market segments. The company's major current market focus is to pharmacy chains, grocery chains with in-store pharmacies, large all purpose retailers with in-store pharmacies, and group buying and chain pharmacy organizations. Although this has been part of the company's plans in the recent past, the difficult litigation with Johnson & Johnson as well as the advent of the July 2013 and July 2016 changes to Medicare reimbursement (and followed by private insurers) and the October 2016 reimbursement engineering, pharmacy business models are now blurred. Thus the company successfully added on-line sales to its business model.

The company has also implemented a very successful "direct to diabetic" business model and has (independently or along with our distributors) executed on-line agreements with several of the largest retail chains, diabetic supply co-operatives, group purchasing organizations, as well as on-line mass merchandisers such as Amacon.com, Ebay, Walmart, Sears, Jet.com and approximately 900 other on-line cooperatives and product aggregators. The company considers this rapid adoption to be a huge success gained in a very short period of time.

In June 2017 we were notified by Amazon.com, the largest retail portal for our products where we sell approximately 20,000 boxes of GenUltimate per month, that the listings for our products had been "hacked" by ghost sellers -- individuals and people who listed our products, accepted orders and cash money from diabetics, but were unknown to the company. Oftentimes product was never delivered to the diabetic even after receipt of payment. This practice called freeloading (by Amazon) is not rare, but once started it is difficult to eradicate. The company had to replace almost 5,000 units of GenUltimate as a result of the freeloading. Further, while freeloaders had a cost basis of zero, legitimate sellers and distributors were forced to compete with these zero cost sellers. Prices for GenUltimate plummeted and by October 2017 the product in its largest portal declined on average by 35%. In May 2018 the company implemented a Phase II Amazon strategy to cull certain sellers of our products from Amazon in an effort to further shore up prices for GenUltimate. This culling process has lowered the number of individual sellers from 26 to 7. Ghost sellers (sellers who sell, then acquire the product for delivery after receipt of monies from the diabetic) are immediately removed from Amazon. The immediate net effect of this process was a liquidation of GenUltimate product from barred sellers, which lowered new order intake for the remainder of Q2 and the early part of Q3. Thus current revenues are flat year to year, despite large growth in product demand, since almost 50% of the company's revenues for what amounts to a retail product come from Amazon re-sales.

With the assistance of Amazon, who themselves became a distributor of GenUltimate!, the company was able to overcome these issues, at least currently. With the assistance of Amazon we reordered our selling practice, implementing base (floor) pricing and implementing real-time policing of listings. Prices for GenUltimate! have recovered about one half of the decline. The company also eliminated many small distributors of GenUltimate! from the other portals by limiting product sales through our wholesalers to these entities. While these actions had the effect of lowering sales in 2Q 2018 (and perhaps 3Q 2018), our margins and our sales levels are recovering.

In March 2017 the company was contacted by the retail giant Walmart, who along with their acquired on-line retailer Jet.com, are attempting to duplicate and surpass the Amazon portal. Our GenUltimate! products have been sold on Walmart's (and Jet's) portals since November 2016. In the recent discussions Walmart offered us preferential listings on portals and Walmart Depot stocking at their regional transit facilities. GenUltimate! will now be sold by Walmart and shipments to diabetics will be fulfilled by Walmart. We accepted the offer and the first sales quarter under this new arrangement have been encouraging. In addition, customers who receive standing orders for their J&J Lifescan test strips will be a part of this new program. The company believes this to be a market enhancing deal since Walmart will become both a "push" and a "pull" retailer. No special pricing of our GenUltimate! pricing is required to implement this plan, owing, no doubt, to the footprint we have established on the on-line portals.

The company in the past has also offered information technology solutions in several medical care market channels by providing physicians with information at the point of care. Our products, unlike those from many other medical information companies, make use of smart cell phones such as the Apple iPhone, the Palm Pre, the Google Droid and a wide selection of Microsoft Windows based smart phones and operate in either in a wireless or "wired" mode, which allow physicians to carry, access and update their patients' histories, also known as electronic medical records or EMR, medication data, and best care guidelines - *all at the point of care*, or from any other location the physician may be located. In addition, the company's products employ proprietary mathematical game theory features adapted by the company for medical use that allow acceptance of diagnoses and treatment protocols where the medical information may have originated from one or several locations and one time or several times. Since the advent of "Obamacare," promising products like our own struggled to gain market acceptance in a reimbursement challenged market. Now with the coming death of "Obamacare" the company cannot yet venture opinions or forecasts for its IT products. While we have kept up with the evolving regulatory changes, we do not foresee implementation of our products and networks in the near future.

In October 2014 we adopted a value added/private label business model to address the issues brought to our market by the radical reimbursement changes by the federal Medicare program. We also hired a market executive with over 40 years of experience to implement our new strategy. We have doubled down on this strategy and now employ not only the services of the aforementioned expert, but also several of his partners and colleagues including the professional who put together the industry's "big box" pharmacy private label plan for diabetic test strips in 2006.

In March 2016 we also retained a product source company called Retail Monster, to represent our products to large drug chains ("big box pharmacy"), large retailers, chain grocers and the like. Unfortunately the arrangement with Retail Monster did not succeed, primarily because a group of company shareholders, former shareholders, and persons claiming to be shareholders poisoned our relationship Retail Monster by advocating, during repeated calls, a "palace coup." After these incursions by shareholders and persons claiming to be shareholders, our relationship with Retail Monster remained cordial but destined to fail. The two companies decided to end the engagement on December 31, 2016. The efforts being expended in the "big-box" arena are greatly aided by the company's recent success with the explosively growing on-line Marketplaces, many sponsored by the large retail pharmacies and retail stores. These Marketplaces are fast growing sister organizations to these retailers, and typically not a part of legacy manufacturers marketing plans. The company's recent successes in the on-line Marketplaces has given the company a beachhead in this market as the uncertainty brought on by the J&J lawsuits has (finally) waned. In mid-March 2016 the largest US retailer agreed to raise the company's standing to the highest retail "rung" by offering a new supplier contract and in mid-March 2018 this retailer and its recently acquired wholesale products partner contacted the company and want to discuss a much enhanced relationship beginning in early April 2018.





Alltara *precis* is not yet available for sale or distribution in the United States or Puerto Rico.

Since March 2015 when we first we acquired special intellectual property and specialty manufacturing equipment which will shall serve our business interests now and into the future. We have increasingly turned to Alpha Capital Anstalt ("Alpha"), Navesink Device Initiatives, Sovereign Partners and Licgo Partners, whereby these organizations either purchased an 18-month 15% OID derivative instruments or Preferred C and/or D stock units, to facilitate the acquisition of intellectual property or manufacturing equipment, or to finance our growth. In 1Q, 2Q and 4Q 2016 and 2Q, 3Q and 4Q 2017 we completed additional financing transactions with both Alpha, Sovereign, and Licgo. Our most recent transactions with Alpha also financed an inventory credit line for the company so that we can meet many of the requirements of the largest retailers and maintain at least $300,000 in stock on hand at any time. Alpha also financed our acquisition of new specialty manufacturing equipment to facilitate our contract manufacturer in Korea as they develop our new GenChoice! product. The company will again turn to Alpha in April as we finance the completion of our GenPrecis! product. As discussed earlier in this report, the company has a total of five new products it has or needs to bring to market

in 2018-2019. We believe that our current financing endeavors with the above named groups can facilitate these product marketing introductions.

On August 1, 2018 the company filed a registration statement under form 1A, Regulation A+, with the U.S. SEC. This "initial" registration was accepted by the SEC for review on August 13, 2018. First SEC staff comments will occur by mid-September 2018. The company is so far undecided whether we will use this registration to raise capital because the tationale for the filing was to take initial steps to resume some sort of financial reporting with the SEC to augment our current reporting with OTCMarkets, Inc.

In the Fall of 2014 the company announced its Discretion cloud wireless glucose monitoring product concepts, which will be manufactured for the company according to spec by its Korean contract manufacturer. In April 2015 the company entered into discussions with HMD Biomedical, Inc. in Taiwan for the importing of HMD's FDA cleared "Cloudia," product as a placeholder until the company's Discretion Messenger product for children would be ready. We ended our discussions with HMD Biomedical in October 2016, after determining that the "Cloudia" product was not robustly developed enough for North American markets and to further develop this product would require another 510(k) approval from the U.S. FDA which we did not wish to undertake. HMD Biomedical has not subsequently enhanced its Cloudia product, but the company has added many if not all of the creative features resident in the Cloudia to its GenPrecis! system, a product of independent design that accomplishes many of the wireless communications in a less expensive manner than originally designed into Cloudia. The company reports that the GenPrecis! system supports these communication features and can be a special product for diabetic children.

The company entered into two international agreements throughout 2017. The first agreement, executed through the company's exclusive Korean agent, allows for delivery of the GenUltimate! and GenSure! (and certainly the GenPrecis! product when available) in quantity for sale in the Korean, Taiwan, Hong Kong, Vietnam and Thailand markets market. As of this writing, the Korean partners have ordered and paid for over 220,000 pieces (units/boxes) of GenUltimate! The company's second international agreement was through a South American financier who has businesses in Bolivia and Spain. This group initially placed a single two-year (term) order for approximately $17 million in GenUltimate! test strips, GenUltimate! meters and the company's new (2017) Firefly! Lancets. The South American financier also notified the company that he and those closely associated with him wished to subscribe to a $3.25 million to $5.0 million capital investment in the company. The group then signed and executed a Subscription Agreement for the company's Preferred D shares in April 2017.

After delivery of approximately 11,000 pieces (units) of GenUltimate!, 3,000 GenUltimate! meters and cases of lancets delivered to Bolivia, the company was contacted by authorities in the U.S. and then again several months later by regulators in Spain concerning the partners and Chinese nationals who were supposedly silent partners involved with this international agreement. As a result of these contacts, the company, on March 20, 2018, terminated the Preferred D Subscription Agreement and terminated the International Distribution Agreement with the Bolivian entities.

In May 2018 the company entered into a wide ranging exclusive agreement with a U.S. concern, for sale of the company's GenUltimate! and GenSure! products in Mexico and parts of South America. Our new distributor subsequently has come to terms with a large Mexican "big box" pharmacy and convenience store chain with over 2,000 locations in Mexico, Chile and Colombia. This agreement has induced the company to change its packaging for its Mexican sales of GenUltimate! and GenSure! and has adopted this packaging for all future International sales.

We have received multiple inquiries from companies interested in perhaps collaborating with the company for the implementation of its cell phone centric technologies MD@Hand and MD@Work. However, the market available for products similar to MD@Hand and MD@Work has changed since its introduction in 2009. The legal challenges to the new health care law and the federal government's inability to enact regulations have altered the landscape, again. We may or may not entertain additional proposed partnerships for our implementation of the cell phone centric technologies, which has been hindered, as has the overall market, by the slow implementation of regulations, protocols and data formats by the Federal government, as well as a change in previously announced Federal government monetary incentives.

Additional Background and Foundation

In May 2010, we entered into agreement with Shasta Technologies, Inc. and Broadtree, Inc. This agreement granted our Pharma Tech Solutions, Inc. subsidiary the exclusive marketing rights to a new diagnostic product not yet on the market named Shasta Genstrip ("Genstrip"). The Genstrip product was developed to compete against the market leader in the then $6.5 billion at home testing market. Shasta was in default of this 2010 Agreement within 90 days of its initiation. Penalties under that agreement and monies owed totaled in excess of $2 million in "delay" penalties, which they were unable to pay. In April 2011, the company renegotiated its agreement changing its many roles and adding responsibility for regulatory approval, manufacturing and forecasting, international sales and additional sales markets in the U.S. Shasta defaulted under this agreement as well. On March 20, 2014 we

acquired the GenStrip intellectual property, its marks and the cleared 510(k). Shasta defaulted on this agreement as well. In addition Shasta breached or defaulted on two insurance settlement agreements, owing to the aforementioned J&J litigation. And finally, Shasta confessed to patent infringement of J&J's three patents.

On April 30, 2014 we first implemented our FDA mandated Quality Plan and are now operating as the manufacturer (operator) of the GenUltimate! test strip. We have implemented subsequent Quality Plans with our Korean contract manufacturer for our GenUltimate! product. Similar Quality Plans and FDA registrations will be in place for the company's GenChoice! and GenPrecis products in the near term, and for our GenAccord and GenCambre products in 2019.

In August 2016 the company settled an insurance matter with Gotham Insurance, an IP Defense insurer, and Shasta covering legal fees associated with the 2011 and 2012 lawsuits brought by Lifescan, Inc. This settlement included a stipulation by Shasta to cease contacting and sharing confidential documents with persons who identified themselves as DECN shareholders. Several of these persons who contacted Shasta also contacted the aforementioned Retail Monster management. The stipulation gained in insurance settlement with Shasta does not preclude the company from pursuing Shasta, its principals and these "shareholders" in its omnibus lawsuit brought against Shasta et al. in 2014. The company filed for Summary Judgment in the Shasta lawsuit in July 2018. The Summary Judgment is being heard in late August 2018. Among other things, Shasta which has been unable to provide documents in the discovery stage of this 2014 suit, nonetheless provided some of these confidential documents to these shareholders, who then posted the information on public message boards. Oddly, the posters of the confidential documents have disappeared.

We currently employ nine professionals at or locally managed through our executive business office located at 2660 Townsgate Road, Suite 300, Westlake Village, California 91361. In addition, we maintain two full-time and seven part-time positions located throughout the United States. We also maintain a Quality Assurance office through our exclusive agent in Seoul, Korea as a means to fulfill our quality commitments to the FDA. Our telephone number is (805) 446-1973 and our website addresses are www.pharmatechsolutionsinc.com and www.genultimate.com. and www.decisiondiagnostics.com. Additional web sites will be added for our GenChoice! product (site in development) and our GenPrecis! product in the Spring of 2018.

As a part of the company's strategic plans, we have applied (to register) for thirteen Trademarks with the USPTO. The company's Genstrip product is a registered Trademark of Shasta Technologies LLC. Our applications were filed with the USPTO in 1Q and 2Q 2015 and throughout 2016 and 2017 and 2018. The company intends to use these Marks, as granted, to brand new products, rebranding of existing products, and the establishment of a family of Marks associated with our company and its place in our industry. As June 30, 2018 the company has received registration confirmation from the USPTO for the following Marks:

"Alltara!"
"GenUltimate!"
"GenSure!"
"GenChoice!"
"GenAccord!"
"GenCambre!"
"GenPrecis!"
"Firefly!"
"ConsumerValue!"
"Infatig"
"Medicius!"

Our marks for Alltara!, ConsumerValue!, Infatig!, and Medicius! will be used for product families as an integral part of our relationships with the "big-box" entities.

We have also applied for Trademarks for our PetSure! and PetUltimate! products in 2Q and 3Q 2018.

Beginning in the 4th Quarter 2015 and through 2nd Quarter 2016 the company suffered severe inventory shortage of the Genstrip 50 product at various times, owing to the timing of the various settlements with Johnson & Johnson by Shasta and a contract manufacturer, Conductive Technologies, Inc. For some period of time Conductive was unable, due to their settlement with Johnson & Johnson, to ship to the company certain quantities of the Genstrip 50 product. This problem began to clear up in late May 2016, and with the advent of adding the GenUltimate! product from Korea, shortages have been alleviated. The company's capacity for GenUltimate! production is now 625,000 packages per month (50 count and 100 count packages), for the new GenSure! product 250,000 packages per month (25 count and 50 count packages) and the new GenChoice! product (initial) 150,000 packages per month (50 count and 100 count packages). Recently, a mega-retailer has requested minimum inventories of finished product of 350,000 units/boxes. We expect other retailers to make similar requests. The manufacture of GenUltimate! and GenSure! are very similar and

this capacity and from a manufacturing standpoint can be viewed as interchangeable. Similarly the manufacture of GenChoice! will be similar to the manufacture of GenAccord! and GenCambre!

The company's stock currently trades on the OTCMarkets OTC Pink Current tier of the market. The company's shares are DTC eligible. On May 12, 2015 the company made an application for a tier change to the OTCQX (common) tier. When the company's common stock fell in price beneath the $.10 threshold, and when our sponsoring broker shuttered his operation, our application went into hiatus. Subsequently, the company received direct communication from OTCMarkets concerning a new uplist program offered, beginning May 18, 2017, whereby the company might uplist within the OTCMarkets tiers as a Current Alternative reporting company and filer. The company reviewed this offer and paid the registration fee, but instead chose another route. On August 1, 2018 the company filed a registration statement with the U.S. SEC under Form 1-A, Regulation A+. The company is undecided whether it will use this registration of securities to raise capital, but the main rationale for the filing was to begin a process of financial reporting again directly to the SEC. On August 13, 2018 the company was contacted by the SEC who did a cursory review of the company's registration and have thus notified the company that they will provide a complete review with first SEC staff comments expected by the middle of September.

Business activities throughout the next twelve months:

The company's business on a day-to-day basis includes the distribution of our GenUltimate! products, (50 count and 100 count versions), distribution of our GenSure! product (25 count and 50 count versions) in Mexico, and late in 2018 our GenChoice! (30 count, 60 count versions) in select International markets. The company's GenPrecis! product will slip to early 2019, unless the company decides to sell a version of GenPrecis! and GenPrecis! Precise meter rebadged as its PetUltimate! (30 count, 60 count versions) and the PetUltimate Avantage meter. Our GenSure! (30 count and 60 count versions) will be sold in Mexico and a few other International markets. In the next 120 days the company will have concluded the clinical analyses and filed for 510K clearance for its GenChoice! product (25 count, 50 count and 100 count versions). The GenChoice! product will ultimately be sold worldwide. Within 180 days of this writing the company will have concluded the clinical analyses and filed for 510K clearance for its GenPrecis! product (25 count, 50 count and 100 count versions and a meter designed with young diabetics in mind). The GenPrecis! product will be sold worldwide and will, most likely, require a strategic partner.

In mid-2017 the company embarked on an ambitious plan to re-brand all of its products, existing and upcoming, to sell into what is more commonly known as the private label marketplace, or the co-brand markets. These markets overlap to a high degree with what is also historically known as the "big-box" market. The rebranding contingency eventually grew to change the entire scope of our products developed for private label sales. In traditional diabetic supplies markets the packages had to include claims made in the original 510K application, plus new international symbiology and UDI identification. Packaging of the products was typically designed to accommodate the capacities of the automation that packaged the products themselves. There was no magic involved with packaging. The 25, 50 and 100 count packages sold by the entire industry grew out of the capabilities of the automated packaging machines, not some grand plan. The entire industry became "me-too." The insurance reimbursement models associated with these 25, 50 and 100 count packages (overwhelmingly 50 count boxes) arose for the same reasons.

Companies in the manufacturing and marketing channels in the industry all employ these packaging processes, including Korean, Chinese and Taiwanese manufacturers. In truth, the manufacturer operations collectively decided not to pay an extra $10,000 for the packaging machines, or the $.10 for a slightly larger strip vial. The company believes this "me-tooism" to be a form of mental blinders. In implementing the company's new private label strategy, Decision Diagnostics decided not to bow to the packaging machine or "me-too" limitations. Instead the new packaging to be employed by the company will take into account diabetic testing patterns and the average number of testing days in a month. Private label versions of the company's products will be packaged in sizes of 30 count, 60 count and 120 count packages. This concept has been readily accepted by the company's private label target list in a detailed survey, and it is believed that this new packaging concept will be a marketing coup. Sales to the private label industry will be through private label product groups where every private label partner will own a private label group, each group containing all of the company's products in selective private label packaging.

The company currently has three major private label targets, the largest drug store chain, another top-5 drug store chain, and the second largest grocery store chain. In addition, the private label packaging is being offered to the largest drug store chains in Mexico and Canada. The Mexican chain, who also has numerous stores in Chile and Argentina has moved quickly. However, in all cases the sales process is in the closing stages. Closes of this nature, do however, take time. The company has Trademarked four product label groups for exclusive sales of products to the private label concerns: Alltara!, Advant!, Infatig!, and Medicius!.

Beginning in November 2009, we introduced our cell-phone centric medical IT products that offer solutions in medical care and management by providing physicians with information at the point of care. Unlike other medical information systems using

standard computer terminals or even palm-sized computers (PDA's), our software applications operate on a series of late generation smart e-cell phones including the Apple iPhone, the Palm Pre, the Google Droid, several makes of RIM's Blackberry and many versions of the Microsoft Windows smart phones. Our products allow physicians to access and update their patients' histories, medication data, and best care guidelines - *all at the point of care*. There are no current plans to sell these products.

Our 12-month business objectives include:

1. The practice of specializing in the distribution of GenUltimate! and GenSure! products, and the completion of the GenChoice! and GenPrecis! products. We also intend to add several brand-name medical diagnostic and medical disposable products (lancets through our Firefly! Product, as well as several lines of insulin syringes and pen needles, all associated with the on-going care of diabetes-inflicted patients, and the world-wide distribution of our proprietary diagnostic products.

2. Combining our wholesale and retail diagnostics distribution with the major successes we have had in the on-line retail markets, and adding legacy retail organizations (already some legacy retailers of note). See discussion above concerning private label opportunities and our private label lines.

3. Continue to implement the plans provided by our agent MWK LLC, and secure big-box pharmacy chains, chain grocers and nationwide retailers in addition to the private label groups previously discussed.

Recent Business Milestones:

In 2Q 2018 the company has accomplished the following milestones.

1. We completed the design and manufacture of GenSure! glucose test strips for the international markets, and completed the advanced development and third party testing of our GenChoice! and GenPrecis! products.
2. We began patient clinical and clinical trials of two new test strip products, our GenChoice! and GenPrecis! test strips and the GenPrecis! Precise meter.
3. We introduced, without fanfare, but with immediate success our PetSure! test strips for the glucose testing of dogs and cats.
4. We are pressing our suit against Johnson & Johnson and several divisions for manufacturing products that infringe on our patents. We won a major early battle in this suit where the trial judge granted us the opportunity to argue the Doctrine of Equivalents, an important concession in this case given J&J's penchant for the twisting of words and drawing lines through random dots. This suit began its prosecution phase on March 15, 2017 with the trial judge's early ruling. We await an important follow up ruling that if in our favor could bring about an end to the case. In August 2018 we filed a soft demand with the trial judge for this ruling.
5. The company initiated a marketing program to the on-line Marketplaces sponsored by pharmacy chain, department store and grocery store retailers, as well as mass merchandisers, and including the largest retailers. This program has so far been the most successful endeavor since our inception.

Financing Requirements

At March 31, 2018, we had cash of $797,858 and negative working capital of $339,229. We anticipate that we will require $68 million in trade debt financing (with velocity of product sales, the $68 million could yield over $500 million in revolving financing) to finance our expected sales of GenUltimate!, GenSure! and GenChoice! In March 2012 we renewed our agreement with Alpha Credit Resources ("ACR") for a third time in order to obtain this debt financing. After the expiration of that agreement, in November 2013 we executed a new line of credit with Alpha Credit Resources, replacing our pervious line. This credit line was for $12.5 million, but with the velocity of our product sales, could yield over $250 million in annually available credit. We never did draw down any credit financing from ACR, and on December 14, 2015 this credit line expired. Subsequently we learned that ACR and its parent, Platinum Partners became the subject of several Federal criminal investigations. In September 2016, the major funds controlled by Platinum filed for liquidation. The company immediately froze all of its securities held by Platinum, and notified the funds liquidator that we had been working with the former management of Platinum to effect return of a sizable majority of the securities held by Platinum. Platinum had not been granted any requests for any conversion or sale transactions since December 2014. As a part of this liquidation the company is now seeking return of most of the securities granted to the Platinum funds from 2007 through 2014.

We will from time to time continue to seek a combination of equity and long-term debt financing as well as other traditional cash flow and asset backed financing to meet our financing needs and to reduce our overall cost of capital. Additionally, in order to accelerate our growth rate and to finance general corporate activities, we may supplement our existing sources of funds with financing arrangements at the operating system level or through additional short-term borrowings. As a further capital resource, we may sell or lease certain rights or assets from our portfolio as appropriate opportunities become available. However, there can be no assurance that we will be able to obtain any additional financing, on acceptable terms or at all.

A. Date and State (or Jurisdiction) of Incorporation:

INCORPORATED IN THE STATE OF NEVADA ON MARCH 2, 2001 AS ATR SEARCH CORPORATION

B. the issuer's primary and secondary SIC Codes;

5122, 7371

C. the issuer's fiscal year end date;

DECEMBER 31

D. principal products or services, and their markets;

GenUltimate! Glucose Test Strips for use with Johnson & Johnson Lifescan glucometer, GenSure!, GenChoice and GenPrecis! glucose test strips and meters. MD@Hand medical communication and EMR software for use with smart cell phones.

7) Describe the Issuer's Facilities

We currently maintain an executive office at 2660 Townsgate Road, Suite 300, Westlake Village, CA 91361. The space consists of approximately 2,300 square feet. The monthly rental for the space is $2,170 per month on a month-to-month basis. We also maintain a Quality Assurance office in at the facility of our exclusive manufacturer's representative in Seoul, Korea. We contract for space in a specialty public warehouse in Miami, FL, which serves as our importing, exporting and shipping and receiving terminal.

8) Officers, Directors, and Control Persons

The goal of this section is to provide an investor with a clear understanding of the identity of all the persons or entities that are involved in managing, controlling or advising the operations, business development and disclosure of the issuer, as well as the identity of any significant shareholders.

A. Names of Officers, Directors, and Control Persons. In responding to this item, please provide the names of each of the issuer's executive officers, directors, general partners and control persons (control persons are beneficial owners of more than five percent (5%) of any class of the issuer's equity securities), as of the date of this information statement.

Our executive officers, directors, and key employees are:

Name	Age	Position
Keith Berman	64	CEO, CFO and Director
Robert Jagunich	71	

Our shareholders elect our directors and our Board of Directors appoints our officers. As of the date of this filing, we have not held an annual meeting. All current directors have been held over until such time the annual meeting is held. Vacancies in our board are filled by the board itself. Set forth below are brief descriptions of the recent employment and business experience of our executive officers and directors.

Keith Berman has served as Chief Financial Officer, Secretary, Treasurer and Director of the Company since January of 2003. He was appointed CEO in July 2017. Mr. Berman has been involved in the development of in-vitro diagnostic products, dry chemistry products, and healthcare software including Intranet and Internet systems for the past 42 years. From July 1999 to present, Mr. Berman has held the position of President, founder and director of Caredecision.net, Inc. a private company engaged in e-health technology development. From March 2001 through June 2002 Mr. Berman also held the Position of President and Director or Medicius, Inc. From January 1996 to June 1999 Mr. Berman was the President and founder of Cymedix, the operating division of Medix Resources, Inc., now Ramp Corp. (RCO). Cymedix was a pioneer company in what was then known as i-health (Internet healthcare) now the e-health industry. Mr. Berman's professional background provides the Company with business management experience and an in depth knowledge of our industry. Mr. Berman received a BA in 1975 and an MBA in 1977, from Indiana University.

Robert Jagunich has served as a Director of the Company since January of 2003. Mr. Jagunich has 27 years of experience in the medical systems and device industry. From August 1992 to present, he has held the position of President at New Abilities Systems, a privately held manufacturer of advanced electronic systems used in rehabilitation. He also provides consulting services to companies such as Johnson and Johnson and has served as a senior executive in such publicly held companies as Laserscope and Acuson. From April 1996 to December 1997 Mr. Jagunich acted as a director of Cymedix Corporation, the operating entity of Medix Resources, Inc., and later, Ramp Corp. (formerly AMEX:RCO). Mr. Jagunich's professional focus on medical devices as well as the professional relationships he has developed throughout his career provides the Company with opportunities to expand current markets and utilize additional product resources not previously available. He received his BS in 1969, and his MS and MBA in 1971, from the University of Michigan.

Mr. Berman, officer and director, works full-time for the company. Mr. Jagunich attends meetings of the board of directors when held and provides 10% and 15% respectively of his business time in professional capacities to the Company.

The following table sets forth information the remuneration of our Principal Executive officer for the years ended December 31, 2016, 2015 and 2014:

Summary Compensation Table

Name and Principal Position	Year	Salary ($)	Bonus ($)	Stock Awards ($)	Option Awards ($)	Non-Equity Incentive Plan Compensation ($)	Nonqualified Deferred Compensation Earnings ($)	All Other Compensation ($)	Total ($)
Keith Berman,	2016	$ -0-	-0-	$ -0-	-0-	-0-	-0-	-0-	$ -0-
CFO and PEO	2017	$ -0-	-0-	$ -0-	-0-	-0-	-0-	-0-	$ -0-
	2018	$ -0-	-0-	$ -0-	-0-	-0-	-0-	-0-	$ -0-

Mr. Berman has served as Chief Financial Officer since January 2003 and as Principal Executive Officer since August 2006. During the fiscal years ended December 31, 2016 and 2017 and through March 31, 2018 Mr. Berman has received no cash compensation. Mr. Berman has not received any form of compensation as a result of our limited cash flow; Mr. Berman has agreed to accept stock awards as his compensation until such time the Company has the necessary resources available to provide a traditional compensation plan.

Name of Beneficial Owner, Officer or Director	Number of Shares	Percent of Outstanding Shares of Common Stock
Keith Berman, CEO, CFO and Director	480,103	<1.0%
Robert Jagunich, Director	929,301	<1.0%
Directors and Officers as a Group	1,409,404	1.11%
Barbara Asbell (founder) 2043 Sunridge Drive Ventura, CA 93030	1,162,590	<1.0%
Directors, Officers and Beneficial Owners as a Group	2,571,994	2.03%

B. Legal/Disciplinary History. Please identify whether any of the foregoing persons have, in the last five years, been the subject of:

1. A conviction in a criminal proceeding or named as a defendant in a pending criminal proceeding (excluding traffic violations and other minor offenses);

   None

2. The entry of an order, judgment, or decree, not subsequently reversed, suspended or vacated, by a court of competent jurisdiction that permanently or temporarily enjoined, barred, suspended or otherwise limited such person's involvement in any type of business, securities, commodities, or banking activities;

   None

3. A finding or judgment by a court of competent jurisdiction (in a civil action), the Securities and Exchange Commission, the Commodity Futures Trading Commission, or a state securities regulator of a violation of federal or state securities or commodities law, which finding or judgment has not been reversed, suspended, or vacated; or

   None

4. The entry of an order by a self-regulatory organization that permanently or temporarily barred suspended or otherwise limited such person's involvement in any type of business or securities activities.

   None

C. Beneficial Shareholders. Provide a list of the name, address and shareholdings or the percentage of shares owned by all persons beneficially owning more than ten percent (10%) of any class of the issuer's equity securities. If any of the beneficial shareholders are corporate shareholders, provide the name and address of the person(s) owning or controlling such corporate shareholders and the resident agents of the corporate shareholders.

   None

9) Third Party Providers

Please provide the name, address, telephone number, and email address of each of the following outside providers that advise your company on matters relating to operations, business development and disclosure:

Administrative Legal Counsel
Name: Thomas C. Cook
Firm: Law Offices of Thomas C. Cook
Address 1: 8250 W. Charleston Blvd. Ste. 120
Address 2: Las Vegas, NV 89117
Phone: (702) 242-0099
Email: tccesq@aol.com

Error Repair

The company will endeavor to repair any and all errors that new sets of eyes find in this document after its posting, whether these errors are in spelling, grammatical, punctuational or numeric. We are not perfect and we remind the readers of this document that they are not perfect either.

10) Issuer Certification

The issuer shall include certifications by the chief executive officer and chief financial officer of the issuer (or any other persons with different titles, but having the same responsibilities).

CERTIFICATION

I, Keith Berman, certify that;

(1) I have reviewed this disclosure statement and Annual Reports for the periods ended June 30, 2018 and December 31, 2017;

(2) Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

(3) Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

(4) The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

(a) designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c) revaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d) disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

(5) I have disclosed, based on our most recent evaluation of the internal control over financial reporting, to the registrant's auditors and the audit committee of registrant's board of directors (or persons performing the equivalent functions):

(a) all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

(b) any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date: August 14, 2018

/s/Keith Berman
Keith Berman
Principal Executive Officer and a Director
(Principal Financial Officer)

CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER AND PRINCIPAL FINANCIAL OFFICER
PURSUANT TO 18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

The undersigned, Keith Berman, the Principal Executive Officer of Decision Diagnostics Corp., and Principal Financial Officer of Decision Diagnostics Corp.,., hereby certifies, that, to his knowledge, the Annual Report of Decision Diagnostics Corp. for the periods ended June 30, 2018 and December 31, 2017, fully complies with the requirements of this Disclosure Statement and of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended, and that the information contained in the Annual Report and this disclosure fairly presents in all material respects the financial condition and results of operations of Decision Diagnostics Corp. and its subsidiaries.

Date: August 14, 2018

/s/Keith Berman
Keith Berman
Principal Executive Officer and
Principal Financial Officer

A signed original of this written statement required by Section 906, or other document authenticating, acknowledging, or otherwise adopting the signatures that appear in typed form within the electronic version of this written statement required by Section 906, has been provided to Decision Diagnostics Corp. and will be retained by Decision Diagnostics Corp. and furnished to any regulatory body or OTC Markets, Inc. or their staff upon request.

Decision Diagnostics Corp.
Condensed Consolidated Balance Sheets
(Unaudited)

	June 30, 2018	December 31, 2017
Assets		
Current assets:		
Cash	$ 797,858	$ 1,088,761
Accounts receivable, net	586,910	437,904
Inventory	163,539	316,659
Prepaid expenses	608,738	859,413
Total current assets	2,157,046	2,702,737
Fixed assets:		
Specialty manufacturing equipment	802,315	802,315
	802,315	802,315
Less accumulated depreciation	-	-
Fixed assets, net	802,315	802,315
Other assets:		
Intellectual property	555,675	551,875
Patent licenses, net value	1,075,825	1,075,825
Total other assets	1,631,500	1,627,700
Total assets	$ 4,590,861	$ 5,132,752
Liabilities and Stockholders' Equity		
Current liabilities:		
Accounts payable and accrued liabilities	$ 812,065	$ 805,555
Accrued interest	42,064	173,433
Contingent legal fees	240,000	240,000
Notes payable and short term debt (Note 5)	1,402,146	2,029,087
Total current liabilities	2,496,275	3,248,074
Contingencies	245,069	245,069
Stockholders' equity (deficit):		
Preferred stock, $0.001 par value, 3,738,500 shares		
authorized, no shares issued and outstanding		
as of June 30, 2018 and December 31, 2017	-	-
Preferred series "B" stock, $0.001 par value, 2,500 shares		
authorized, 1,000 issued and outstanding		
as of June 30, 2018 and December 31, 2017	2	2
Preferred series "C" stock, $0.001 par value, 10,000 shares		
authorized, 6,893 and 6,473 shares issued and outstanding		
as of June 30, 2018 and December 31, 2017	6	6
Preferred series "D" stock, $0.001 par value, 500 shares		
authorized, 40 shares issued and outstanding as of		
as of June 30, 2018 and December 31, 2017	-	-
Preferred series "E" stock, $0.001 par value, 1,250,000 shares		
authorized, 882,540 and 813,240 issued and outstanding		
as of June 30, 2018 and December 31, 2017	882	813
Common stock, $0.001 par value, 494,995,000 shares authorized,		
126,643,110 and 110,231,610 shares issued and outstanding		
as of June 30, 2018 and December 31, 2017	126,434	110,032
Common stock unissued, 1,410,000 shares		
as of June 30, 2018 and December 31, 2017	1,411	1,411
Subscription receivable	(82,250)	(82,250)
Unit offering finders' fees	(321,344)	(321,344)
Additional paid-in capital	47,612,968	46,288,346
Retained (deficit)	(45,488,592)	(44,357,408)
Total stockholders' equity	1,849,516	1,639,608
Total liabilities and stockholders' equity	$ 4,590,861	$ 5,132,752

The accompanying Notes are an integral part of these financial statements.

Decision Diagnostics Corp.
Condensed Consolidated Statements of Operations
(Unaudited)

	Three Months Ended June 30,		Six Months Ended June 30,	
	2018	**2017**	**2018**	**2017**
Revenue	$ 430,483	$ 422,740	$ 989,487	$ 777,802
Cost of sales	324,754	292,799	670,928	547,332
Gross profit	105,729	129,941	318,559	230,470
Expenses:				
General & administrative expenses	134,586	94,778	281,204	215,491
Consulting	40,331	16,089	72,016	63,286
Compensation expense	126,293	97,431	234,414	201,052
Professional fees	208,340	377,719	654,491	562,153
Total expenses	509,550	586,017	1,242,125	1,041,983
Net operating (loss)	(403,821)	(456,076)	(923,566)	(811,513)
Other income (expense):				
Financing costs	(98,611)	(7,000)	(104,611)	(27,515)
Interest expense, net	(55,528)	(59,877)	(102,937)	(119,754)
Loss on terminated contract	-	(83,472)	-	(83,472)
Total other income (expense)	(154,139)	(150,349)	(207,548)	(230,741)
Taxes:				
State	(70)	-	(70)	-
Net loss	$ (558,030)	$ (606,425)	$ (1,131,184)	$ (1,042,254)
Add: Dividends declared on preferred stock	-	-	-	-
Income available to common shareholders'	$ (558,030)	$ (606,425)	$ (1,131,184)	$ (1,042,254)
Weighted average number of common shares outstanding - basic and fully diluted	123,011,140	90,703,841	118,422,915	89,350,772
Net loss per share - basic and fully diluted	$ (0.00)	$ (0.01)	$ (0.01)	$ (0.01)

The accompanying Notes are an integral part of these financial statements.

Decision Diagnostics Corp.

Statements of Shareholders' Equity

(Unaudited)

		Preferred "B"		Preferred "C"		Preferred "D"		Preferred "E"		Common Stock			Authorized	Subscription	Finders'	Retained	
Date	Shareholder	# Shares	Amt	# Shares	Amt	# Shares	Amt	# Shs	Amt	# Shs	Amt	APIC	Unissued	Receivable	Fees	(Deficit)	Total
BALANCE, DECEMBER 31, 2017		*1,000*	*2*	*6,473*	*6*	*40*	*-*	*813,240*	*813*	*110,231,610*	*110,032*	*46,288,346*	*1,411*	*(82,250)*	*(321,344)*	*(44,357,408)*	*1,639,608*
1/8/18	New Issuance-Alpha Capital Anstalt									1,504,281	1,504	151,932					153,437
1/18/18	New Issuance-Robert Herskowitz							100,000	100	-	-	5,900					6,000
2/9/18	New Issuance-Alpha Capital Anstalt									1,496,661	1,497	151,163					152,659
2/23/18	New Issuance-Robert Herskowitz							(100,000)	(100)	1,400,000	1,400	(1,300)					-
2/23/18	New Issuance-Chase Financing Inc Profit Sh.							(70,000)	(70)	980,000	980	(910)					-
3/5/18	New Issuance-Alpha Capital Anstalt									1,510,797	1,511	152,590					154,101
3/31/18	New Issuance-Alpha Capital Anstalt									1,521,904	1,522	153,712					155,234
	Net loss															*(573,155)*	*(573,155)*
BALANCE, MARCH 31, 2018		*1,000*	*2*	*6,473*	*6*	*40*	*-*	*743,240*	*743*	*118,645,253*	*118,446*	*46,901,434*	*1,411*	*(82,250)*	*(321,344)*	*(44,930,563)*	*1,687,885*
4/3/18	New Issuance-Mark Herskowitz									849,123	849	85,761					86,611
4/16/18	New Issuance-Alpha Capital Anstalt									1,513,789	1,514	152,893					154,406
4/16/18	New Issuance-Chase Financing Inc Profit Sh.							100,000	100	-	-	5,900					6,000
4/23/18	New Issuance-Alpha Capital Anstalt									1,039,571	1,040	104,997					106,036
5/11/18	New Issuance-LICGO Partners			420	-					-	-	-					-
5/11/18	New Issuance-Chase Financing Inc Profit Sh.							100,000	100	-	-	5,900					6,000
5/29/18	New Issuance-Alpha Capital Anstalt									1,985,374	1,985	200,523					202,508
5/29/18	New Issuance-Robert Herskowitz									1,550,000	1,550	156,550					158,100
6/11/18	New Issuance-Chase Financing Inc Profit Sh.							(75,000)	(75)	1,050,000	1,050	(975)					-
	Immaterial reconciling items							14,300	14	10,000	-	(14)					-
	Net loss															*(558,030)*	*(558,030)*
BALANCE, JUNE 30, 2018		*1,000*	*2*	*6,893*	*6*	*40*	*-*	*882,540*	*882*	*126,643,110*	*126,434*	*47,612,968*	*1,411*	*(82,250)*	*(321,344)*	*(45,488,592)*	*1,849,517*

Decision Diagnostics Corp.		
Consolidated Statements of Cash Flows		
(Unaudited)		
	Six Months Ended June 30,	
	2018	2017
Cash flows from operating activities		
Net loss	$ (1,131,184)	$ (1,042,254)
Adjustments to reconcile net loss to		
net cash (used) by operating activities:		
Amortization of prepaid legal fees	250,000	250,000
Shares and options issued for services	-	21,400
Options issued for employee compensation	-	36,000
Shares issued for financing fees	104,611	27,515
Loss on terminated contract		83,472
Changes in operating assets and liabilities	-	
Accounts receivable	(149,006)	(96,624)
Inventory	153,120	104,523
Prepaid and other assets	675	1,164
Accounts payable and accrued liabilities	6,511	84,691
Contingent legal fees	-	-
Accrued interest	102,937	36,282
Net cash (used) by operating activities	(662,338)	(493,831)
Cash flows from investing activities		
Fixed assets	-	(64,890)
Intellectual property	(3,800)	(43,245)
Net cash (used) by investing activities	(3,800)	(108,135)
Cash flows from financing activities		
Proceeds from notes payable	375,235	-
Subscriptions payable	-	-
Shares issued and options exercised for cash	-	-
Net cash provided by financing activities	375,235	-
Net decrease in cash	(290,903)	(601,966)
Cash - beginning	1,088,761	1,351,860
Cash - ending	$ 797,858	$ 749,894
Supplemental disclosures:		
Interest paid	$ -	$ -
Income taxes paid	$ 70	$ -
Non-cash transactions:		
Shares and options issued for services	$ -	$ 21,400
Options issued for compensation	$ -	$ 36,000
Shares issued for financing activities	$ 104,611	$ 27,515
Shares issued for debt and derivative liabilities	$ 1,236,481	$ 501,086
The accompanying Notes are an integral part of these financial statements.		

NOTE 1 – Basis of presentation and accounting policies

Basis of Presentation

The condensed consolidated interim financial statements included herein, presented in accordance with United States generally accepted accounting principles and stated in US dollars, have been prepared by us, without audit, pursuant to the rules and regulations of the Securities and Exchange Commission. Certain information and footnote disclosures normally included in financial statements prepared in accordance with generally accepted accounting principles have been condensed or omitted pursuant to such rules and regulations, although we believe that the disclosures are adequate to make the information presented not misleading.

These statements reflect all adjustments, consisting of normal recurring adjustments, which, in the opinion of management, are necessary for fair presentation of the information contained therein. It is suggested that these consolidated interim financial statements be read in conjunction with our consolidated financial statements for the period ended December 31, 2017 and notes thereto included in our annual filing. We follow the same accounting policies in the preparation of consolidated interim reports.

Results of operations for the interim periods are not indicative of annual results.

Recent Accounting Pronouncements

Management has analyzed all pronouncements issued during the three months ended June30, 2018 by the FASB or other authoritative accounting standards groups with future effective dates, and have determined that they are not applicable or are not expected to be significant to our financial statements.

Year-end

We have adopted December 31 as our fiscal year end.

NOTE 2 – Going concern

The accompanying consolidated financial statements have been prepared assuming that we will continue as a going concern. Our ability to continue as a going concern is dependent upon attaining profitable operations based on the development of distributions platforms through which our products that can be sold. We intend to use borrowings and security sales to mitigate the effects of our cash position, however, no assurance can be given that debt or equity financing, if required, will be available. The condensed consolidated financial statements do not include any adjustments relating to the recoverability and classification of recorded assets and classification of liabilities that might be necessary should we be unable to continue in existence.

NOTE 3 – Fair value

Our financial instruments consist principally of notes payable and lines of credit. Notes payable and lines of credit are financial liabilities with carrying values that approximate fair value. Management determines the fair value of notes payable and lines of credit based on the effective yields of similar obligations and believe all of the financial instruments' recorded values approximate fair market value because of their nature and respective durations.

We comply with the provisions of ASC 820, *"Fair Value Measurements and Disclosures"* ("ASC 820"). ASC 820 defines fair value, establishes a framework for measuring fair value and expands disclosures about fair value measurements required under other accounting pronouncements. ASC 820-10-35, *"Fair Value Measurements and Disclosures - Subsequent Measurement"* ("ASC 820-10-35"), clarifies that fair value is an exit price, representing the amount that would be received from the sale of an asset or paid to transfer a liability in an orderly transaction between market participants. ASC 820-10-35 also requires that a fair value measurement reflect the assumptions market participants would use in pricing an asset or liability based on the best information available. Assumptions include the risks inherent in a particular valuation technique (such as a pricing model) and/or the risks inherent in the inputs to the model. The Company also follows ASC 825 *"Interim Disclosures about Fair Value of Financial Instruments"*, to expand required disclosures.

ASC 820-10-35 establishes a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (level 1 measurement) and the lowest priority to unobservable inputs (level 3 measurements). The three levels of the fair value hierarchy under ASC 820-10-35 are described below:

Level 1. Valuations based on quoted prices in active markets for identical assets or liabilities that an entity has the ability to access.

Level 2. Valuations based on quoted prices for similar assets or liabilities, quoted prices for identical assets or liabilities in markets that are not active, or other inputs that are observable or can be corroborated by observable data for substantially the full term of the assets or liabilities.

Level 3. Valuations based on inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.

We utilize the best available information in measuring fair value. The following table summarizes, by level within the fair value hierarchy, the financial assets and liabilities recorded at fair value on a recurring basis as of June 30, 2018:

	FYE 2018 Fair Value Measurements			
	Level 1	Level 2	Level 3	Total Fair Value
Assets				
Intellectual property	$ -	$ -	$ 1,631,500	$ 1,631,500
Liabilities	-	-	-	-
Notes payable	-	(1,402,146)	-	(1,402,146)
Total	$ -	$ (1,402,146)	$ 1,631,500	$ 229,354

NOTE 4 – Equipment – Specialty Manufacturing Instruments

On June 1, 2015, we entered into a wide-ranging manufacturing and product development agreement with a venture funded Korean R&D and manufacturing concern with a specialty in diabetic test strip technologies. On July 8, 2015, we enhanced the role of this concern through agreements and through the purchase of, and investment in, computer controlled, specialty manufacturing equipment for our GenUltimate! products, which now include our GenSure! and PetUltimate! products, and in 2016 we invested further for our GenChoice! products, which now include our PetSure! products. All of the specialty manufacturing instruments are located in the Korean facility of the Company's R&D and contract manufacturing partner. Throughout 2016 and 2017 we augmented this equipment by adding additional equipment capable of manufacturing our GenPrecis!, GenAccord! and GenCambre! products that use different molds and chemical processes.

During the quarter ended March 31, 2017, we acquired $64,890 in fixed assets pursuant to the manufacturing and product development agreement dated June 1, 2015. We expensed an additional $380,000 for the development of our GenChoice! product which will make use of the Specialty Manufacturing equipment located in Korea. We continue to incur great expense due to development of our GenChoice! product during the quarter ending June 30, 2018.

NOTE 5 – Patents

During the quarters ended June 30, 2018 and 2017, we capitalized attorney fees related to the continued development and perfection of our patents. We did not amortize any intellectual property or patents during the quarters ended June 30, 2018 and 2017.

NOTE 6 – Acquisition of Certain Properties

In March 2014, we agreed to acquire certain properties from Shasta Technologies LLC. The agreement covering this acquisition became the subject of two litigations, one litigation related to the remaining proceeds of an IP defense insurance policy which partially provided an insurance defense for our 2011-2016 litigationd with Lifescan, Inc. a division of Johnson & Johnson. The other litigations still on-going but the subject to a Summary Judgment Motion filed by the company, concerns damages the company is trying to collect from Shasta Technologies LLC owing to Shasta's subsequent undisclosed, and fatal issues with the U.S. FDA. The litigation concerning the IP insurance defense policy has subsequently been settled with the insurer and their agents. The company's Summary Judgment Motion in the latter litigation is set to be heard later in August 2018.

The original purchase price for this property was expected to be $2,000,000 (cash). The company is anticipating offsets much higher than the assets purchase price. We have not yet recorded this acquisition on our books because the acquisition terms have not yet been fully determined and the final acquisition price will be determined by the court. Should the company's Summary Judgment Motion be granted by the court this litigation will be completed and the company will seek expert opinion regarding the fair value of the properties. We did register this FDA cleared product under our FDA Establishment registration (with the US FDA) in 2014, 2015, 2016, 2017 and in 2018. In September 2016 we became fully compliant with the newly implemented FDA UDI product identification initiative.

NOTE 7 – Notes payable

We have recorded interest and financing expense in connection with our notes payable totaling $55,528 and $59,877 and $98,611 and $7,000 for the quarters ended June 30, 2018 and 2017, respectively.

NOTE 8 – Stockholder's equity

2018 Issuances

Preferred

During the quarter ended June 30, 2018, we issued 420 shares of preferred series "C" shares for financing costs valued at less than $1.

During the quarter ended June 30, 2018, we issued 200,000 shares of preferred series "E" shares for financing costs valued at $12,000.

During the quarter ended June 30, 2018, holders of our preferred series "E" shares elected to convert 75,000 preferred series "E" shares into 1,050,000 shares of our $0.001 par value common stock.

Common

During the quarter ended June 30, 2018, we issued 6,088,734 shares of $0.001 par value common stock for conversion of debt and accrued interest totaling $621,051.

During the quarter ended June 30, 2018, we issued 849,123 shares of $0.001 par value common stock for financing costs of $86,611.

NOTE 9 – Stock options

2017 Stock Option Plan

During the quarter ended March 31, 2017, we adopted the "2017" Executive and Key Man/Woman Stock Option Plan and granted incentive and nonqualified stock options with rights to purchase 450,000 shares of $0.001 par value common stock at the strike price of $.08 per share. As of March 31, 2018, all options allowed under the plan have been granted and are exercisable at the election of the holder.

The following is a summary of activity of outstanding stock options under all Stock Option Plans:

	Number of Shares	Weighted Average Exercise Price
Balance, January 1, 2017	8,600,000	$ 0.10
Options granted	450,000	.08
Options cancelled	-	-
Options exercised	-	-
Balance, December 31, 2017	9,050,000	$ 0.10
Balance, January 1, 2018	9,050,000	$ 0.10
Options granted	-	-
Options cancelled	-	-
Options exercised	-	-
Balance, June 30, 2018	9,050,000	$ 0.10

NOTE 10 – Commitments and Contingencies

Contingencies and Litigation

We transact commerce in several medical products market channels. We also transact commerce by licensing our proprietary medical software that functions by moving confidential medical data through our proprietary medical information technology devices and networks. Our GenUltimate! product (originally called GenStrip and GenStrip 50) required initial regulatory approval by the US FDA as well as on-going US FDA approvals during the product life cycle (known as post-market oversight) and are subject to this FDA regulation and post market overview. In 2016, we had to meet new FDA Guidelines for product identification, tracking and standardization. Our new GenChoice! and GenPrecis! and the later upcoming GenAccord! and GenCambre! products will follow the same pathway with the U.S. FDA. The FDA calls its new product identification program, the UDI initiative, and the new packaging required, and met by us, approximates a similar standard implemented in the European Union in 2013, and then adopted in other countries, Korea for example. We are now filing for approvals in the EU and in Mexico, through our exclusive agent, for our GenSure!, GenUltimate! and GenChoice! products, after having received certain approvals in Central and South America.

Further, our products required medical patient trials and several compete directly with a major platform manufacturer. Healthcare, especially those segments where the company competes, is a very litigious. Competing companies often use litigation as a marketing (market depriving) tool, bringing litigation as a means to protect market share and limit market exposure even though market limitation through litigation is illegal. We have in the past (and currently) defended cases brought by Plaintiffs asserting these types of claims.

The medical industry is also intertwined. From time to time, we have become involved in claims and litigation that arise out of the normal course of business, such as litigation that emerges from disputes over damaged, missing or contaminated product, litigation that arises over payment disputes or claims of fair value. We have also had to defend trade dress claims filed solely because of the cost to defend these claims, real or not. For instance, we have been sued in several jurisdictions over a single business transaction. Often these cases involve substantial over-prosecution where we and our have been held accountable by Plaintiffs for a myriad of things including words written or posted in public forums by anonymous persons.

We may also become involved in disputes that arise over the business or business practices of our suppliers, payers and customers, people or entities that we may not be familiar with. We maintain substantial insurance coverage against suits that may arise over issues of damaged, recalled or counterfeit product and other product liability issues. We have also been a victim of the unapproved acts of prior management. These acts have resulted in claims from individuals and entities since the Board relieved former management of duty in 2006. Nonetheless, these claims have resulted in the use of management time and company resources to investigate, litigate, or settle. In addition, we accrue contingent legal fees and product liability fees. As of June 30, 2018, our contingent legal fees accrual was $240,000 and our general contingencies accrual was $245,069. Contingencies total $485,069 and are reflected herein.

From time to time, we may also be subject to demands from individuals or entities. These demands and disputes may consume management time and company resources. Other than as noted below, if there is such a disclosure, there are no pending matters at the current time that in management's judgment may be considered material or potentially material.

Leases

We currently maintain an executive office at 2660 Townsgate Road, Suite 300, Westlake Village, CA 91361. The space consists of approximately 2,300 square feet. The monthly rental for the space is $2,170 per month on a month-to-month basis. We also maintain space in a public warehouse in Miami, FL, and we are granted space indirectly in Seoul, South Korea for the completion of necessary clinical trials.

Rent expense totaled $6,510 and $6,510 for the quarters ended June 30, 2018 and 2017, respectively.

NOTE 11 – Subsequent events

In accordance with ASC 855, management evaluated all of our activities through the issue date of the financial statements and concluded that no other subsequent events have occurred that would require recognition or disclosure in the financial statements. We do however discuss all subsequent events in our Managements' Discussion and Analysis documents and filings.

After eight months of no action by the court, on August 10, 2018 the company, through several subsidiaries, filed a formal letter, subject to (Nevada) Federal Court local rules, requesting a judicial determination of a Summary Judgment filed in August 2017 filed by Defendant Johnson & Johnson. A finding by the court in the company's favor should provide impetus to settle the case given that Johnson & Johnson ("J&J") cannot appeal a denial of their Motion. Should the J&J Motion be granted, the company will immediately appeal to the Federal Circuit Court of Appeals in Washington, DC.

On August 8, 2018, a Canadian financier representing charity and "do good" angels and special situations funds in the U.S. and Canada, contacted the company, through its agent, in an effort to negotiate a possible $6 million long term investment. Because the company's products appeal to uninsured and underinsured diabetics, the company qualifies as a "do good" concern. The terms of this possible investment could materialize quickly in the next 10 days.

All remaining Subsequent Events, if any, are discussed in greater detail in the company's Management's Discussion and Analysis section for 2Q 2018.